[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 61394
1. Hohenstein B, Kuo MC, Addabbo F, Yasuda K, Ratliff B, Schwarzenberger C, Eckardt KU, Hugo CP, Goligorsky MS: Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. Am J Physiol Renal Physiol; 2010 Jun;298(6):F1504-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney.
  • Primary and/or secondary injury of the renal microvascular endothelium is a common finding in various renal diseases.
  • However, these mechanisms have so far not been studied after selective microvascular injury in the kidney.
  • The present study investigated the time course of EPC and HSC stimulation and homing following induction of selective EC injury in the mouse kidney along with various angiogenic factors potentially involved in EC repair and progenitor cell stimulation.
  • Progenitor cells could be first detected in the circulation and the spleen before they selectively homed to the diseased kidney.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1994 Mar 24;368(6469):339-42 [8127368.001]
  • [Cites] J Exp Med. 1995 Jul 1;182(1):219-31 [7790818.001]
  • [Cites] Dev Dyn. 1995 Apr;202(4):325-32 [7626790.001]
  • [Cites] Kidney Int. 1995 Dec;48(6):1846-56 [8587244.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1099-112 [9777941.001]
  • [Cites] Nat Med. 1999 Apr;5(4):434-8 [10202935.001]
  • [Cites] Ann N Y Acad Sci. 1999 Apr 30;872:71-82 [10372112.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Kidney Int. 1999 Sep;56(3):794-814 [10469350.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16(3):658-66 [15689404.001]
  • [Cites] Kidney Int. 2005 Apr;67(4):1216-33 [15780075.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):997-1004 [15744001.001]
  • [Cites] Kidney Int. 2005 May;67(5):1925-33 [15840040.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1525-31 [15905185.001]
  • [Cites] Exp Cell Res. 2005 Oct 15;310(1):105-16 [16112109.001]
  • [Cites] Kidney Int. 2005 Nov;68(5):1932-6 [16221168.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Dec;16(6):593-609 [16046180.001]
  • [Cites] Cardiovasc Res. 2006 Apr 1;70(1):61-9 [16448633.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4):932-42 [16481411.001]
  • [Cites] J Mol Cell Cardiol. 2006 Apr;40(4):455-64 [16438981.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jul;291(1):F176-85 [16478972.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(7):823-5 [17351666.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H274-83 [17337594.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7 [10725398.001]
  • [Cites] Genesis. 2000 Oct;28(2):75-81 [11064424.001]
  • [Cites] J Am Soc Nephrol. 2001 Jul;12(7):1448-57 [11423573.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):599-608 [11485918.001]
  • [Cites] J Pathol. 2001 Sep;195(2):229-35 [11592103.001]
  • [Cites] Kidney Int. 2007 Oct;72(8):926-30 [17609688.001]
  • [Cites] J Cereb Blood Flow Metab. 2008 Jan;28(1):90-8 [17519976.001]
  • [Cites] Nephrol Dial Transplant. 2008 Apr;23(4):1144-56 [18045820.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1950-9 [18818421.001]
  • [Cites] Clin Sci (Lond). 2009 Feb;116(3):219-30 [19118493.001]
  • [Cites] Cytokine. 2009 Mar;45(3):174-8 [19147372.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1095 [11822359.001]
  • [Cites] J Am Soc Nephrol. 2002 Mar;13(3):806-16 [11856789.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1285-90 [12234298.001]
  • [Cites] Circulation. 2002 Dec 3;106(23):2973-9 [12460881.001]
  • [Cites] Nat Med. 2003 Jun;9(6):702-12 [12778169.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;996:49-60 [12799282.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):553-62 [12875975.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1340-6 [12702503.001]
  • [Cites] J Cardiovasc Pharmacol. 2003 Oct;42(4):527-33 [14508239.001]
  • [Cites] Kidney Int. 2003 Nov;64(5):1648-52 [14531796.001]
  • [Cites] Blood. 2004 Feb 1;103(3):921-6 [14525788.001]
  • [Cites] Contrib Nephrol. 1979;16:109-14 [467060.001]
  • [Cites] Kidney Int. 1991 Jul;40(1):29-34 [1921152.001]
  • [Cites] Blood. 1992 May 1;79(9):2221-5 [1571537.001]
  • (PMID = 20237239.001).
  • [ISSN] 1522-1466
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK045462; United States / NIDDK NIH HHS / DK / DK-052783; United States / NIDDK NIH HHS / DK / DK-054602; United States / NIDDK NIH HHS / DK / DK-45462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 11096-26-7 / Erythropoietin; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ PMC2886821
  •  go-up   go-down


2. Orr A, Willis S, Holmes M, Britton P, Orr D: Living with a kidney transplant: a qualitative investigation of quality of life. J Health Psychol; 2007 Jul;12(4):653-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living with a kidney transplant: a qualitative investigation of quality of life.
  • Research has shown that transplantation improves quality of life for patients with end stage renal disease (ESRD), although it does not return to pre-kidney failure levels.
  • This study used focus groups to explore the experience of living with a transplanted kidney.
  • These may necessitate constant vigilance, reduced spontaneity and preoccupation with self-care to maintain the kidney's health; being treated differently from others; pressure not to let themselves and others down; and the urge to increase their knowledge about their condition.
  • [MeSH-major] Kidney Transplantation. Quality of Life. Survivors / psychology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584816.001).
  • [ISSN] 1359-1053
  • [Journal-full-title] Journal of health psychology
  • [ISO-abbreviation] J Health Psychol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Anastasiadis A, Dimitriadis G, Radopoulos D: Incidental giant renal oncocytoma: a case report. J Med Case Rep; 2010;4:358
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental giant renal oncocytoma: a case report.
  • INTRODUCTION: Large renal oncocytomas are not very rare entities.
  • The tumor was incidentally diagnosed and, based on the preoperative clinical and radiographic findings, was therefore considered to be a renal cell carcinoma.
  • CASE PRESENTATION: A 48-year-old Caucasian diabetic man had an abdominal ultrasound for chronic abdominal discomfort, which revealed a large mass on the left kidney.
  • A magnetic resonance imaging scan was performed with no evidence of renal vein or caval thrombus or embolus.
  • A radical nephrectomy was performed through a left flank intercostal incision and the pathology diagnosed renal oncocytoma.
  • CONCLUSION: Several reports have characterised this essentially benign renal histiotype, which represents 5% to 7% of all solid renal masses.
  • Unfortunately, most renal oncocytomas cannot be differentiated from malignant renal cell carcinomas by clinical or radiographic criteria.
  • These tumors are treated operatively with radical or partial nephrectomy or thermal ablation, depending on the clinical circumstances.
  • We report on, to the best of our knowledge, the fourth largest lesion of this type of renal pathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21059248.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990760
  •  go-up   go-down


Advertisement
4. Su W, Fang C, Yang HC, Gu Y, Hao CM: [Expression of nestin in human kidney and its clinical significance]. Zhonghua Bing Li Xue Za Zhi; 2008 May;37(5):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of nestin in human kidney and its clinical significance].
  • OBJECTIVE: To study the expression and significance of nestin (a type of cytoskeletal protein) in normal and diseased human kidneys.
  • METHODS: Diseased kidney tissues were obtained from needle biopsies in 32 patients with glomerulonephritis (including 8 cases of membranous glomerulopathy, 3 cases of focal segmental glomerulosclerosis, 17 cases of IgA nephropathy with proteinuria and 4 cases of IgA nephropathy without proteinuria).
  • Control kidney tissues were obtained from nephrectomy specimens for renal tumors.
  • The expression of nestin in the control kidney tissues was studied using immunoelectronic microscopy and immunohistochemistry.
  • The expression of nestin in the diseased kidney tissues was detected by immunohistochemistry and real-time reverse transcription-polymerase chain reaction.
  • RESULTS: In normal kidney tissues, nestin was detected at the periphery of glomerular capillary loops.
  • However, the glomerular nestin expression levels in cases of IgA nephropathy with proteinuria, membranous glomerulopathy and focal segmental glomerulosclerosis were significantly lower than those in the normal kidneys and IgA nephropathy without proteinuria.
  • CONCLUSION: Nestin may play an important role in maintaining the normal function of podocytes in human kidney.
  • [MeSH-minor] Adult. Gene Expression Regulation. Humans. Immunohistochemistry. Kidney. Kidney Diseases / metabolism. Kidney Diseases / pathology. Kidney Glomerulus / metabolism. Kidney Glomerulus / pathology. Middle Aged. Nestin. Proteinuria / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956648.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


5. Simmons WN, Cocks FH, Zhong P, Preminger G: A composite kidney stone phantom with mechanical properties controllable over the range of human kidney stones. J Mech Behav Biomed Mater; 2010 Jan;3(1):130-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A composite kidney stone phantom with mechanical properties controllable over the range of human kidney stones.
  • A novel composite kidney stone phantom has been developed.
  • This stone phantom is producible with mechanical properties mimicking the range of tensile fracture strength and acoustic properties of human kidney stones and is an inorganic/organic composite material, as are natural kidney stones.
  • Diametral compression testing was used to measure tensile fracture strength, which determines the acoustic comminution behavior of kidney stones.
  • Both the tensile fracture strength (controllable from 1 to approximately 5 MPa) and acoustic properties (C(L) = 2700-4400 m/s and C(T)=1600-2300m/s) of these composite phantom stones match those of a wide variety of human kidney stones.
  • [MeSH-major] Kidney Calculi / physiopathology. Phantoms, Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acoust Soc Am. 2002 Oct;112(4):1265-8 [12398432.001]
  • [Cites] J Urol. 1986 Dec;136(6):1367-72 [3773122.001]
  • [Cites] J Urol. 2000 Aug;164(2):537-44 [10893640.001]
  • [Cites] J Acoust Soc Am. 1993 Jul;94(1):29-36 [8354759.001]
  • [Cites] J Endourol. 1993 Dec;7(6):437-44 [8124332.001]
  • [Cites] J Endourol. 1995 Dec;9(6):449-52 [8775072.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2598-608 [16200192.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2005 Nov;75(2):351-8 [16088905.001]
  • [Cites] Ultrasound Med Biol. 2002 May;28(5):661-71 [12079703.001]
  • [Cites] J Biomech Eng. 2002 Feb;124(1):133-4 [11871599.001]
  • [Cites] J Biomed Mater Res. 1989 May;23(5):507-21 [2715163.001]
  • (PMID = 19878912.001).
  • [ISSN] 1878-0180
  • [Journal-full-title] Journal of the mechanical behavior of biomedical materials
  • [ISO-abbreviation] J Mech Behav Biomed Mater
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052985; United States / NIDDK NIH HHS / DK / R01 DK052985; United States / NIDDK NIH HHS / DK / R37 DK052985
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS498637; NLM/ PMC3756310
  •  go-up   go-down


6. Nezami N, Tarzamni MK, Argani H, Nourifar M: Doppler ultrasonographic indexes in kidney transplant recipients: its relationship with kidney function. Iran J Kidney Dis; 2007 Oct;1(2):82-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doppler ultrasonographic indexes in kidney transplant recipients: its relationship with kidney function.
  • INTRODUCTION: Doppler ultrasonography (DU) is mostly used for assessment of both graft and native kidneys' vascular status.
  • In this study, correlation between the DU indexes and kidney allograft function was evaluated.
  • MATERIALS AND METHODS: Hospital records of 273 kidney transplant patients (154 men and 119 women) were reviewed.
  • In all cases, DU had been performed 1 month after kidney transplantation.
  • We evaluated the data on the resistive index (RI) and pulsatility index (PI) in the interlobar arteries and renal artery stenosis (RAS), and renal vessels thrombosis were determined.
  • Concurrent serum creatinine and cyclosporine values were assessed in relation to the DU findings.
  • RESULTS: The RI and PI had significant linear correlations with serum creatinine (P = .03 and P = .002, respectively).
  • Also, there were direct linear correlations between the age of the patients and the RI and PI values.
  • Despite this finding, RI and PI were significantly lower in patients with RAS than in the patients with patent renovascular tributary (0.59 +/- 0.15 versus 0.65 +/- 0.11; P = .03 and 1.02 +/- 0.40 versus 1.18 +/- 0.46; P = .049, respectively).
  • There were no associations between serum cyclosporine level or panel reactive antibodies and the RI or PI.
  • CONCLUSIONS: The RI and PI are valuable DU markers for determining the kidney allograft function and the related vascular complications.
  • [MeSH-major] Kidney Transplantation / ultrasonography. Renal Artery Obstruction / ultrasonography. Thrombosis / ultrasonography


7. Weiss AS, Smits G, Wiseman AC: Standard criteria donor pancreas donation status is associated with improved kidney transplant outcomes. Clin Transplant; 2009 Sep-Oct;23(5):732-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard criteria donor pancreas donation status is associated with improved kidney transplant outcomes.
  • BACKGROUND: Organ donor characteristics can be used to predict outcomes in kidney transplantation.
  • We hypothesized that pancreas donation status could reflect organ quality and be predictive of kidney graft outcomes following Standard Criteria Donor (SCD) kidney transplantation.
  • METHODS: We performed a retrospective analysis of deceased donor kidney alone (DD KA) transplants reported to SRTR from 1992 to 2005.
  • Group 1 = kidney alone recipients from pancreas donors (KA, P+) and Group 2 = kidney alone recipients from non-pancreas donors (KA, P-).
  • CONCLUSION: Donor pancreas donation status is an independent predictor of improved outcomes of SCD kidney recipients.
  • Further study of the pancreas organ donor pre-procurement is warranted to optimize not only pancreas utilization but also kidney graft outcomes.
  • [MeSH-major] Graft Rejection / prevention & control. Graft Survival / physiology. Kidney Transplantation. Pancreas Transplantation. Tissue Donors. Tissue and Organ Procurement / standards


8. Park SB, Cho KS, Lee JH, Jeong YK, Choi SH, Kang BS, Kim JK: Unusual manifestations of renal cell carcinoma. Acta Radiol; 2008 Sep;49(7):839-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual manifestations of renal cell carcinoma.
  • The imaging characteristics of renal cell carcinoma (RCC) vary widely, with masses ranging from cystic to solid, from homogeneous to heterogeneous and necrotic, from small to large, and from localized to extensive.
  • In this pictorial review, we describe the following unusual imaging features: unusual subtypes, unusual tumor growth, unusual underlying disease, multiple and bilateral presentations, hemorrhage and arteriovenous fistula (AVF)-related presentations, and mimicking of benign tumors.
  • Familiarity with the imaging features of both usual and unusual RCCs will facilitate prompt and accurate diagnosis and treatment.
  • [MeSH-major] Carcinoma, Renal Cell / diagnostic imaging. Kidney Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143067.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 15
  •  go-up   go-down


9. Friedman AL, Peters TG, Jones KW, Boulware LE, Ratner LE: Fatal and nonfatal hemorrhagic complications of living kidney donation. Ann Surg; 2006 Jan;243(1):126-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal and nonfatal hemorrhagic complications of living kidney donation.
  • OBJECTIVE: After anecdotal reports of severe hemorrhage from failure of surgical clips to sustain closure of renal artery stumps in live donor nephrectomies were received, this study was designed to identify specific surgical techniques that are associated with an increased risk of failure to control bleeding and might represent opportunities to improve patient safety.
  • BACKGROUND: Preventing complications for living kidney donors must be paramount in addressing end-stage renal failure through living kidney donation.
  • Open and laparoscopic approaches to living kidney donation use several vascular control methods, some of which may be more prone to failure and life-endangering hemorrhage than others.
  • METHODS: To define hemorrhagic complications of living kidney donation, a survey was sent to all 893 surgeon-members of the American Society of Transplant Surgeons.
  • Descriptive and bivariate analyses were used to ascertain study participant characteristics, most frequently used vascular control techniques, and incidence of events (death, transfusion, reexploration or conversion to open nephrectomy, or contralateral [remaining kidney] renal failure).
  • Among arterial control problems, 2 resulted in donor death and 2 resulted in renal failure; 19 episodes required transfusion.
  • Locking and standard clips applied to the renal artery were associated with the greatest risks.
  • CONCLUSIONS: Significant hemorrhagic complications occur with living kidney donation in both open and laparoscopic approaches.
  • [MeSH-major] Hemorrhage / etiology. Kidney Transplantation / adverse effects. Living Donors. Nephrectomy / adverse effects. Surgical Instruments / adverse effects

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Transplant. 1999 Feb;13(1 Pt 2):108-12 [10081646.001]
  • [Cites] Am J Transplant. 2003 Jul;3(7):830-4 [12814474.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1491-6 [10589945.001]
  • [Cites] Transplantation. 2000 Jun 15;69(11):2319-23 [10868632.001]
  • [Cites] Clin Transplant. 2000 Aug;14(4 Pt 2):433-8 [10946784.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):149-64 [11505060.001]
  • [Cites] Clin Transplant. 2002;16 Suppl 7:62-8 [12372047.001]
  • [Cites] Am J Transplant. 2002 Nov;2(10):959-64 [12482149.001]
  • [Cites] Transplant Proc. 2003 Mar;35(2):835-7 [12644157.001]
  • [Cites] Am J Transplant. 2003 Jul;3(7):775-85 [12814469.001]
  • [Cites] Am Surg. 1999 Mar;65(3):197-204 [10075290.001]
  • [Cites] J Urol. 2004 Jan;171(1):47-51 [14665841.001]
  • [Cites] JAMA. 2004 Jan 21;291(3):325-34 [14734595.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):358-63 [15273562.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):374-81 [15325606.001]
  • [Cites] Surgery. 2004 Oct;136(4):881-90 [15467675.001]
  • [Cites] N Engl J Med. 1995 Aug 10;333(6):333-6 [7609748.001]
  • [Cites] Transplantation. 1995 Nov 15;60(9):1047-9 [7491680.001]
  • [Cites] J Am Soc Nephrol. 1996 Nov;7(11):2288-313 [8959619.001]
  • [CommentIn] Ann Surg. 2006 Oct;244(4):629; author reply 629-30 [16998373.001]
  • (PMID = 16371747.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1449959
  •  go-up   go-down


10. Shoji T, Ishimura E, Nishizawa Y: Body fat measurement in chronic kidney disease: implications in research and clinical practice. Curr Opin Nephrol Hypertens; 2007 Nov;16(6):572-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body fat measurement in chronic kidney disease: implications in research and clinical practice.
  • PURPOSE OF REVIEW: The paradoxical and inverse association between body mass index and mortality risk in patients with end-stage renal disease has raised a question of whether an increased fat mass is good or bad for patients with chronic kidney disease.
  • The purpose of this review is to update the concept on body fat in patients with chronic kidney disease.
  • Following the initiation of dialysis, chronic kidney disease patients gain body weight due mainly to increased fat mass.
  • In predialysis chronic kidney disease, there is also an inverse association between body mass index and mortality risk.
  • The metabolic syndrome and a high body mass index are independent predictors for development of chronic kidney disease and end-stage renal disease, respectively.
  • In diabetic patients with chronic kidney disease, however, a high initial body mass index is associated with a slower decline in glomerular filtration rate.
  • SUMMARY: The impacts of fat mass on survival and renal function appear to vary depending upon the absence or presence, and stages of chronic kidney disease.
  • Further research is required for optimal nutritional management and improved outcomes of patients with chronic kidney disease.
  • [MeSH-major] Adipose Tissue. Kidney Failure, Chronic / pathology
  • [MeSH-minor] Anthropometry. Humans. Kidney Function Tests. Predictive Value of Tests. Survival Rate

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089973.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


11. de Klerk M, Zuidema WC, Ijzermans JN, Weimar W: On chain lengths, domino-paired and unbalanced altruistic kidney donations. Clin Transpl; 2009;:247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On chain lengths, domino-paired and unbalanced altruistic kidney donations.
  • Kidney transplantations with living related and unrelated donors are the optimal option for patients with end-stage renal disease.
  • For patients with a willing--but blood-type or HLA incompatible donor--a living-donor kidney exchange program could be an opportunity.
  • In Asia, the United States and Europe, kidney exchange programs were developed under different conditions, with different exchange algorithms, and with different match results.
  • The easiest way to organize a living-donor kidney exchange program is to enlist national or regional cooperation, initiated by an independent organization that is already responsible for the allocation of deceased donor organs.
  • For incompatible donor-recipient pairs who have been unsuccessful in finding suitable matches in an exchange program, domino-paired kidney transplantations triggered by Good Samaritan donors is the next alternative.
  • If no Good Samaritan donors are available, an unbalanced kidney paired-exchange program with compatible and incompatible pairs is another strategy that merits future development.
  • [MeSH-major] Altruism. Kidney Transplantation / statistics & numerical data. Living Donors / psychology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524290.001).
  • [ISSN] 0890-9016
  • [Journal-full-title] Clinical transplants
  • [ISO-abbreviation] Clin Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR, Alberta Kidney Disease Network: Prevalence of chronic kidney disease and survival among aboriginal people. J Am Soc Nephrol; 2007 Nov;18(11):2953-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of chronic kidney disease and survival among aboriginal people.
  • Globally, it is known that the incidence of end-stage renal disease is higher among Aboriginals, but it is unknown whether this is due to an increased prevalence of chronic kidney disease or other unidentified factors.
  • We studied 658,664 people of non-First Nations and 14,989 people of First Nations and found that the age- and sex-adjusted prevalence of chronic kidney disease was significantly higher among those of non-First Nations compared to those of First Nations (67.5 versus 59.5 per 1000 population; P < 0.0001).
  • However, severe chronic kidney disease (estimated glomerular filtration rate <30 ml/min per 1.73 m2) was almost two-fold higher among people of First Nations (P < 0.0001).
  • Cox proportional hazards models suggested that compared to people of non-First Nations, those of First Nations with chronic kidney disease had a 77% increased risk of death after adjusting for age, gender, diabetes and baseline eGFR.
  • In conclusion, whether the higher incidence of end-stage renal disease among people of First Nations is due to suboptimal management of chronic kidney disease and its associated comorbidities, more rapid loss of kidney function, or other unidentified factors remains to be determined.
  • [MeSH-major] Indians, North American / statistics & numerical data. Kidney Diseases / ethnology. Kidney Diseases / mortality


13. Fearnley C, Wakeley PR, Gallego-Beltran J, Dalley C, Williamson S, Gaudie C, Woodward MJ: The development of a real-time PCR to detect pathogenic Leptospira species in kidney tissue. Res Vet Sci; 2008 Aug;85(1):8-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of a real-time PCR to detect pathogenic Leptospira species in kidney tissue.
  • To assess the suitability of these PCR methods for diagnosis, a trial was performed on kidneys taken from adult pigs with evidence of leptospiral infection, primarily a history of reproductive disease and serological evidence of exposure to pathogenic leptospires (n=180) and aborted pig foetuses (n=24).
  • In a subsidiary experiment, the 'pathogenic' PCR was used to analyse kidney samples from rodents (n=7) collected as part of vermin control in a zoo, with show animals with high microagglutination titres to Leptospira species, and five were positive.
  • Fifteen PCR amplicons from 1 mouse, 2 rat and 14 pig kidney samples, were selected at random from positive PCRs (n=30) and sequenced.
  • The only successful culture was from this mouse kidney and the isolate was confirmed to be L. inadai by classical serology.
  • [MeSH-major] Kidney / microbiology. Leptospira / isolation & purification. Leptospirosis / veterinary. Polymerase Chain Reaction / veterinary. Swine Diseases / microbiology
  • [MeSH-minor] Animals. Kidney Diseases / microbiology. Kidney Diseases / veterinary. Swine. Temperature

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961617.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Reisaeter AV, Røislien J, Henriksen T, Irgens LM, Hartmann A: Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant; 2009 Apr;9(4):820-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy and birth after kidney donation: the Norwegian experience.
  • Reports on pregnancies in kidney donors are scarce.
  • Linkage with the Norwegian Renal Registry provided data on pregnancies of kidney donors 1967-2002.
  • A random sample from the Medical Birth Registry was control group, as was pregnancies in kidney donors prior to donation.
  • No differences were observed in the occurrence of adverse pregnancy outcome in kidney donors and in the general population in unadjusted analysis.
  • Our finding of more frequent preeclampsia in pregnancies after kidney donation in the secondary analysis must be interpreted with caution, as the number of events was low.


15. Girgin C, Sezer A, Sahin O, Oder M, Dinçel C: Giant renal calculus in a solitary functioning kidney. Urol Int; 2007;78(1):91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant renal calculus in a solitary functioning kidney.
  • We report a case of giant renal calculus 230 x 140 mm in size and weighing 1,350 g in a solitary functioning kidney treated by nephrolithotomy.
  • A giant renal calculus in his right kidney and atrophic nonfunctioning left kidney was diagnosed by ultrasonography, IVP and CT scan.
  • This case is the largest and the heaviest stone reported in the literature in a solitary functioning kidney.
  • [MeSH-major] Kidney Calculi
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Nephrostomy, Percutaneous. Tomography, X-Ray Computed. Urodynamics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192742.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Go AS, Lo JC: Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease. Curr Opin Nephrol Hypertens; 2006 May;15(3):296-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease.
  • PURPOSE OF REVIEW: To review recent literature about the relationship between non-dialysis-requiring chronic kidney disease and cardiovascular disease as well as possible explanatory factors.
  • This risk is not linearly associated with level of kidney function.
  • Chronic kidney disease is associated with a larger burden of traditional vascular risk factors but is also linked to abnormalities in a variety of nontraditional pathways such as dysregulation of mineral metabolism and arterial calcification, vessel stiffness and endothelial dysfunction, insulin resistance, inflammation, malnutrition, and anemia, among others.
  • Other novel kidney-specific proteins (e.g. renalase) may play direct mediating roles.
  • The relative contribution of these factors to excess cardiovascular disease in chronic kidney disease remains unclear.
  • SUMMARY: Recent evidence demonstrates the importance of non-dialysis-requiring chronic kidney disease as a potent predictor of cardiovascular disease and its complications.
  • Randomized trials should be performed to determine whether modification of traditional and nontraditional risk factors can reduce incident cardiovascular disease as well as which interventions can optimize treatment outcomes in persons with chronic kidney disease and cardiovascular disease.
  • [MeSH-major] Cardiovascular Diseases / epidemiology. Kidney Diseases / epidemiology
  • [MeSH-minor] Chronic Disease. Glomerular Filtration Rate. Humans. Renal Dialysis. Risk Factors

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609298.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 67
  •  go-up   go-down


17. Hansberry MR, Whittier WL, Krause MW: The elderly patient with chronic kidney disease. Adv Chronic Kidney Dis; 2005 Jan;12(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The elderly patient with chronic kidney disease.
  • The elderly are a fast growing population in the United States, and they have a high prevalence of chronic kidney disease.
  • The elderly are particularly susceptible to kidney damage from age-related declines in glomerular filtration as well as kidney damage from chronic disease states such as diabetes mellitus, hypertension, glomerular, and tubulointerstitial disorders.
  • A significant number of elderly individuals are reaching end-stage renal disease that require renal replacement therapy.
  • This expanding population provides a challenge for health-care providers because the elderly are often referred late to a nephrologist, have a shortened survival on renal replacement therapy as compared with younger individuals, and suffer from more comorbidities such as cardiovascular disease, malnutrition, and hearing and visual disabilities.
  • The elderly also have difficulties with dialysis vascular access and often are not candidates for renal transplantation.
  • Despite these obstacles, age alone is not a justification for withholding diagnostic or therapeutic interventions, because many elderly individuals have an improvement in their quality of life and social support once their kidney disease is identified and treated.
  • [MeSH-major] Kidney Failure, Chronic / epidemiology
  • [MeSH-minor] Age Factors. Aged. Disease Susceptibility / epidemiology. Humans. Prevalence. Renal Replacement Therapy / utilization. Risk Factors. United States / epidemiology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719336.001).
  • [ISSN] 1548-5595
  • [Journal-full-title] Advances in chronic kidney disease
  • [ISO-abbreviation] Adv Chronic Kidney Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


18. Ruppar TM, Russell CL: Medication adherence in successful kidney transplant recipients. Prog Transplant; 2009 Jun;19(2):167-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medication adherence in successful kidney transplant recipients.
  • OBJECTIVE: To explore the medication-taking behavior of successful kidney transplant recipients and determine what behaviors were common among this group.
  • METHODS: Open-ended interviews were conducted by telephone with 19 individuals who had successfully maintained a transplanted kidney for 25 years or more.
  • RESULTS: Four themes emerged as participants described the behaviors they developed to adhere successfully to the immunosuppressive medication required for maintaining their transplanted kidneys.
  • Kidney transplant recipients identified the importance of developing and maintaining medication-taking skills and routines on medication adherence.
  • CONCLUSIONS: Interventions focusing on medication-taking skills, habit formation, and resources for problem solving may improve immunosuppressive medication adherence and clinical outcomes in kidney transplant recipients.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Oct 27;70(8):1240-4 [11063348.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):e25-146 [18086926.001]
  • [Cites] Clin Transplant. 2001 Oct;15(5):330-6 [11678959.001]
  • [Cites] Transplant Proc. 2003 Mar;35(2):796-7 [12644142.001]
  • [Cites] J Healthc Qual. 2003 Mar-Apr;25(2):20-5 [12659076.001]
  • [Cites] Clin Nurse Spec. 2003 Jul;17(4):200-8; quiz 209-30 [12869867.001]
  • [Cites] Am J Hosp Pharm. 1979 Oct;36(10):1321-5 [507073.001]
  • [Cites] Transplantation. 1995 Feb 15;59(3):340-7 [7871562.001]
  • [Cites] Clin Transplant. 1997 Dec;11(6):618-22 [9408696.001]
  • [Cites] J Heart Lung Transplant. 1998 Sep;17(9):854-63 [9773856.001]
  • [Cites] Manag Care Interface. 2004 Sep;17(9):44-8 [15521285.001]
  • [Cites] Am J Transplant. 2007 Dec;7(12):2704-11 [17868065.001]
  • [Cites] Am J Kidney Dis. 2007 Feb;49(2):294-300 [17261432.001]
  • [Cites] Clin Transplant. 2006 May-Jun;20(3):359-68 [16824155.001]
  • [Cites] Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):347-52 [16268422.001]
  • [Cites] Kidney Int. 2001 Oct;60(4):1565-70 [11576374.001]
  • (PMID = 19588667.001).
  • [ISSN] 1526-9248
  • [Journal-full-title] Progress in transplantation (Aliso Viejo, Calif.)
  • [ISO-abbreviation] Prog Transplant
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA092656; United States / NCI NIH HHS / CA / R24 CA092656; United States / NINR NIH HHS / NR / P30 NR003979; United States / NINR NIH HHS / NR / P30 NR003979-15; None / None / / P30 NR003979-15
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS266536; NLM/ PMC3071038
  •  go-up   go-down


19. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, Druml W, Böhmig GA: Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation; 2005 Mar 27;79(6):696-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients.
  • BACKGROUND: Kidney transplant recipients with a current positive complement-dependent cytotoxicity crossmatch (CDCXM) are at high risk for hyperacute rejection and graft loss.
  • In this analysis, we evaluated effectiveness of peritransplant IA as an anti-humoral strategy to overcome a current positive CDCXM in presensitized renal allograft recipients.
  • METHODS: Between 1999 and 2003, 40 high risk cadaveric kidney allograft recipients (median CDC panel reactive antibody [PRA] level, 77%; number of retransplants, n = 38) were subjected to peritransplant IA with protein A (one pretransplant IA session followed by a course of repeat posttransplant IA sessions) in addition to preemptive antilymphocyte antibody therapy.
  • CONCLUSION: Our results demonstrate that peritransplant IA enables successful cadaveric kidney transplantation in the context of a positive CDCXM.
  • [MeSH-major] Graft Survival / immunology. Histocompatibility Testing. Immunosorbents / immunology. Kidney Transplantation / immunology


20. Schukfeh N, Kuebler JF, Schirg E, Petersen C, Ure BM, Glüer S: Dysplastic kidney and not renal agenesis is the commonly associated anomaly in infants with seminal vesicle cyst. BJU Int; 2009 Mar;103(6):816-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplastic kidney and not renal agenesis is the commonly associated anomaly in infants with seminal vesicle cyst.
  • OBJECTIVE: To determine whether the association of seminal vesicle cyst (SVC) and renal anomaly in young children correlates with previously reported cases of SVCs in adolescent and adult patients, as congenital SVCs, although rare, are frequently described in association with ipsilateral renal agenesis, mainly in adolescent and adult patients, whereas reports on SVCs in younger children are sparse.
  • PATIENTS AND METHODS: We report on nine infants (median age 4 months) with congenital SVCs, all of them associated with ipsilateral dysplastic kidneys.
  • All patients had ultrasonography of the renal system and voiding cysto-urethrography.
  • RESULTS: The SVCs were found incidentally during ultrasonography for the renal anomaly.
  • Three patients had dysplastic and six had multicystic dysplastic kidneys.
  • In previous reported adult cases of SVCs the most common associated renal anomaly was agenesis of the ipsilateral kidney (25 of 44 cases), whereas only one case of dysplastic kidney was reported.
  • CONCLUSION: As the appearance of renal agenesis might result from a former congenital dysplastic kidney, our findings indicate that cases of ipsilateral renal agenesis in adult patients with congenital SVCs might represent former dysplastic or multicystic dysplastic kidney.
  • [MeSH-major] Cysts / etiology. Genital Diseases, Male / etiology. Kidney / abnormalities. Multicystic Dysplastic Kidney / complications. Seminal Vesicles

  • Genetic Alliance. consumer health - Urogenital adysplasia, hereditary.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040535.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Langer R, Tóth A, Máthé Z, Remport A, Járay J, Kahan BD: [Lymphocele and kidney transplantation]. Orv Hetil; 2007 Aug 5;148(31):1475-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphocele and kidney transplantation].
  • INTRODUCTION: Lymphocele is a special complication following kidney transplantation.
  • The authors examined the factors associated with an increased occurrence of clinically significant perinephric fluid collections and/or lymphoceles among sirolimus-treated renal transplant recipients.
  • In both subgroups the serum creatinine levels were elevated at the time of diagnosis from a nadir of 179.5 +/- 141.7 to 359.9 +/- 259.6 mmol/l (Group III, sirolimus treated) and from 222.6 +/- 205.9 to 383.7 +/- 255.2 mmol/l (Group IV, sirolimus free).
  • Despite an Influenza A + Chlamydia pneumonia and acute rejection which was followed by a GI bleeding and stomach resection he fully recovered and is doing well with an excellent kidney function a year after.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Lymphocele / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656338.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


22. Yaqoob MM: Acidosis and progression of chronic kidney disease. Curr Opin Nephrol Hypertens; 2010 Sep;19(5):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acidosis and progression of chronic kidney disease.
  • PURPOSE OF REVIEW: Chronic kidney disease progressively impairs the ability of kidneys to excrete hydrogen ions owing to the reduced capacity of the kidney to synthesize ammonia resulting in metabolic acidosis.
  • There is good experimental evidence that metabolic acidosis contributes to protein energy wasting disorder and progression of chronic kidney disease (CKD).
  • RECENT FINDINGS: Three recent publications have confirmed the experimental evidence and the only randomized controlled study of its kind has suggested that the correction of acidosis by sodium bicarbonate in patients with advanced CKD is associated with attenuation of the rate of decline of renal function, reduction in the incidence of end stage renal disease and improvement of nutritional parameters.
  • SUMMARY: In light of these recent studies, it appears that this cheap and simple strategy, which is in line with current renal recommendations, has the potential of translating into significant economic, quality of life and clinical outcome benefits in an expanding pool of patients with CKD.
  • [MeSH-major] Acidosis / complications. Kidney Diseases / complications
  • [MeSH-minor] Animals. Disease Progression. Glomerular Filtration Rate. Humans. Kidney / physiopathology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20539229.001).
  • [ISSN] 1473-6543
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


23. Ishibe S, Cantley LG: Epithelial-mesenchymal-epithelial cycling in kidney repair. Curr Opin Nephrol Hypertens; 2008 Jul;17(4):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal-epithelial cycling in kidney repair.
  • PURPOSE OF REVIEW: Tubule repair following acute kidney injury involves epithelial de-differentiation followed by cell migration and proliferation and eventual re-differentiation.
  • RECENT FINDINGS: Epithelial de-differentiation after kidney injury or in epithelial culture systems is controlled by secreted factors such as transforming growth factor beta and hepatocyte growth factor as well as cell-cell and cell-matrix interactions.
  • SUMMARY: This review focuses on the underlying molecular mechanism of epithelial de-differentiation and re-differentiation in tubule repair in vivo and formation in vitro, thus giving insight into possible strategies for improving recovery following acute kidney injury and preventing progression to chronic kidney disease.
  • [MeSH-major] Epithelium / physiology. Kidney / physiology. Mesoderm / physiology
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Humans. Kidney Diseases / pathology. Kidney Diseases / physiopathology. Kidney Tubules / growth & development. Kidney Tubules / physiology. Wnt Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660674.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 58
  •  go-up   go-down


24. Yen M, Huang JJ, Teng HL: Education for patients with chronic kidney disease in Taiwan: a prospective repeated measures study. J Clin Nurs; 2008 Nov;17(21):2927-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education for patients with chronic kidney disease in Taiwan: a prospective repeated measures study.
  • AIM: To investigate the physical, knowledge and quality of life outcomes of an educational intervention for patients with early stage chronic kidney disease.
  • BACKGROUND: A comprehensive predialysis education care team can be effective in slowing the progression of chronic kidney disease.
  • A predialysis, team-delivered educational intervention covering renal function health care, dietary management of renal function and the effects of Chinese herb medication on renal function was designed and implemented.
  • Study outcomes included physical indicators, knowledge (renal function protection, use of Chinese herbs and renal function and diet) and quality of life.
  • The primary indicator of renal function, glomerular filtration rate, remained stable throughout the 12 months of follow-up, despite the relatively older mean age of study participants.
  • CONCLUSION: A predialysis education care team can provide effective disease-specific knowledge and may help retard deterioration of renal function in persons with early-stage chronic kidney disease.
  • [MeSH-major] Kidney Diseases / physiopathology. Patient Education as Topic

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012761.001).
  • [ISSN] 1365-2702
  • [Journal-full-title] Journal of clinical nursing
  • [ISO-abbreviation] J Clin Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Caixeta A, Mehran R: Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv; 2010 Mar 1;75 Suppl 1:S15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury.
  • Contrast-induced acute kidney injury (CI-AKI) is one of the leading causes of hospital-acquired acute kidney injury.
  • CI-AKI is highly prevalent in patients with well-known risk factors, including older age, chronic renal insufficiency, congestive heart failure, and diabetes.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Contrast Media / adverse effects. Kidney Diseases / prevention & control. Radiography, Interventional / adverse effects

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. DOPAMINE .
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20333702.001).
  • [ISSN] 1522-726X
  • [Journal-full-title] Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • [ISO-abbreviation] Catheter Cardiovasc Interv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Protective Agents; 8MDF5V39QO / Sodium Bicarbonate; INU8H2KAWG / Fenoldopam; VTD58H1Z2X / Dopamine; WYQ7N0BPYC / Acetylcysteine
  • [Number-of-references] 47
  •  go-up   go-down


26. Danovitch GM, Delmonico FL: The prohibition of kidney sales and organ markets should remain. Curr Opin Organ Transplant; 2008 Aug;13(4):386-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prohibition of kidney sales and organ markets should remain.
  • RECENT FINDINGS: In 'natural experiments' performed in developing countries the outcome for kidney vendors, in terms of both their medical and psychosocial health, has been shown to be poor.
  • SUMMARY: Commercialization of living kidney donation does not serve the interests of the donors, endangers the health of recipients, and undermines the healthy development of the international transplant endeavor.
  • [MeSH-major] Financing, Organized / legislation & jurisprudence. Government Regulation. Health Policy / economics. Kidney Transplantation / economics. Living Donors / legislation & jurisprudence. Tissue and Organ Procurement / economics
  • [MeSH-minor] Altruism. Cost-Benefit Analysis. Crime / prevention & control. Gift Giving. Health Care Costs. Health Services Accessibility / economics. Health Services Accessibility / legislation & jurisprudence. Health Services Needs and Demand / economics. Health Services Needs and Demand / legislation & jurisprudence. Humans. Motivation. Organizational Objectives. Public Opinion. Renal Dialysis / economics. Risk Assessment. United States. Waiting Lists

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685334.001).
  • [ISSN] 1531-7013
  • [Journal-full-title] Current opinion in organ transplantation
  • [ISO-abbreviation] Curr Opin Organ Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


27. Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, Gipson D, Colindres RE, Kshirsagar AV: SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med; 2007 Feb 26;167(4):374-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease.
  • BACKGROUND: Despite the wide availability and low cost of serum creatinine measurement, at-risk populations are not routinely tested for chronic kidney disease (CKD).
  • METHODS: We used a cross-sectional analysis of a nationally representative, population-based survey to develop a system, SCORED (SCreening for Occult REnal Disease), that uses routinely available demographic and medical information to identify individuals with an increased likelihood of CKD.
  • Chronic kidney disease was defined as a glomerular filtration rate less than 60 mL/min per 1.73 m(2).
  • CONCLUSION: This scoring system, weighted toward common variables associated with CKD, may be a useful tool to identify individuals with a high likelihood of occult kidney disease.
  • [MeSH-major] Creatinine / blood. Kidney Failure, Chronic / diagnosis. Mass Screening / methods. Models, Biological. Population Surveillance


28. Barbari AG, Masri MA, Stephan AG, El Ghoul B, Rizk S, Mourad N, Kamel GS, Kilani HE, Karam AS: Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study. Exp Clin Transplant; 2006 Jun;4(1):400-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study.
  • OBJECTIVES: To determine prospectively the temporal variations of cyclosporine-A lymphocyte maximum level, whole blood maximum concentration, and total lymphocyte count in patients with de novo kidney transplantation.
  • MATERIALS AND METHODS: Lymphocyte maximum level, whole blood maximum concentration, and total lymphocyte count were prospectively measured in 35 patients at 1, 2, and 3 months after kidney transplantation.
  • Cyclosporine-A lymphocyte maximum level seems to offer a more reliable alternative than does whole blood maximum concentration for cyclosporine-A monitoring in patients with kidney transplantation.
  • [MeSH-major] Cyclosporine / blood. Immunosuppressive Agents / blood. Kidney Transplantation. Lymphocytes / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827634.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


29. van der Mei SF, van Sonderen EL, van Son WJ, de Jong PE, Groothoff JW, van den Heuvel WJ: Social participation after successful kidney transplantation. Disabil Rehabil; 2007 Mar 30;29(6):473-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Social participation after successful kidney transplantation.
  • PURPOSE: To explore and describe the degree of social participation after kidney transplantation and to examine associated factors.
  • METHOD: A cross-sectional study on 239 adult patients 1-7.3 years after kidney transplantation was performed via in-home interviews on participation in obligatory activities (i.e., employment, education, household tasks) and leisure activities (volunteer work, assisting others, recreation, sports, clubs/associations, socializing, going out).
  • RESULTS: Kidney transplantation patients had a lower educational level, spent less time on obligatory activities, had part-time jobs more often, and participated less in sports compared to a control group from the general population.
  • CONCLUSIONS: Although kidney transplantation patients participate less in employment and sports, they do participate in household tasks, volunteer work, going out, socializing and other leisure activities.
  • [MeSH-major] Activities of Daily Living. Employment. Interpersonal Relations. Kidney Transplantation. Leisure Activities

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364802.001).
  • [ISSN] 0963-8288
  • [Journal-full-title] Disability and rehabilitation
  • [ISO-abbreviation] Disabil Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Hahn H: Genetics of kidney development: pathogenesis of renal anomalies. Korean J Pediatr; 2010 Jul;53(7):729-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of kidney development: pathogenesis of renal anomalies.
  • Congenital anomalies of the kidney and urinary tract (CAKUT) account for more than 50% of abdominal masses found in neonates and involve about 0.5% of all pregnancies.
  • CAKUT has a major role in renal failure, and increasing evidence suggests that certain abnormalities predispose to the development of hypertension and cardiovascular disease in adulthood.
  • To understand the pathogenesis of human renal anomalies, understanding the development of kidney is important.
  • Diverse anomalies of the kidney corresponding to defects at a particular stage of development have been documented recently; however, more research is required to understand the molecular networks underlying kidney development, and such an investigation will provide a clue to the therapeutic intervention for CAKUT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int Suppl. 1997 Dec;63:S124-7 [9407439.001]
  • [Cites] Eur Urol. 1975;1(6):287-93 [1233198.001]
  • [Cites] J Am Soc Nephrol. 2008 May;19(5):891-903 [18305125.001]
  • [Cites] J Am Soc Nephrol. 2008 Apr;19(4):825-31 [18235093.001]
  • [Cites] Cell. 1995 Apr 21;81(2):289-98 [7736581.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Oct;36(10):1868-73 [15203099.001]
  • [Cites] J Am Soc Nephrol. 2009 Jan;20(1):23-35 [19118152.001]
  • [Cites] Nat Rev Genet. 2007 Oct;8(10):791-802 [17878895.001]
  • [Cites] Dev Biol. 2006 Nov 15;299(2):466-77 [17022962.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8090-5 [15141091.001]
  • [Cites] Dev Cell. 2004 May;6(5):709-17 [15130495.001]
  • [Cites] Pediatr Nephrol. 2009 Oct;24(10):1913-9 [19190936.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):321-33 [16452504.001]
  • [Cites] Nat Rev Genet. 2005 Dec;6(12):928-40 [16341073.001]
  • [Cites] Science. 1996 May 31;272(5266):1339-42 [8650545.001]
  • [Cites] J Am Soc Nephrol. 2004 Apr;15(4):998-1007 [15034102.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):616-32 [17357069.001]
  • [Cites] Kidney Int. 2007 Feb;71(3):195-200 [17183244.001]
  • [Cites] Bioessays. 2006 Feb;28(2):117-27 [16435290.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:509-29 [16822174.001]
  • [Cites] Clin Genet. 2006 Feb;69(2):105-17 [16433689.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):384-5 [9398836.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):358-64 [7795640.001]
  • [Cites] Development. 2003 Jul;130(14):3175-85 [12783789.001]
  • [Cites] N Engl J Med. 2003 Jan 9;348(2):101-8 [12519920.001]
  • [Cites] Kidney Int. 2002 Mar;61(3):889-98 [11849443.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):666-9 [11792949.001]
  • [Cites] Pediatr Dev Pathol. 2000 May-Jun;3(3):223-31 [10742409.001]
  • [Cites] J Am Soc Nephrol. 2010 Jan;21(1):113-23 [19959718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20386-91 [18077349.001]
  • [Cites] Neuron. 1998 Jul;21(1):53-62 [9697851.001]
  • [Cites] Br J Urol. 1988 Oct;62(4):295-300 [3191352.001]
  • [Cites] J Am Soc Nephrol. 2001 Oct;12(10):2175-80 [11562418.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):109-17 [11438459.001]
  • [Cites] Semin Fetal Neonatal Med. 2008 Jun;13(3):142-51 [18065301.001]
  • [Cites] Development. 2007 Jul;134(13):2397-405 [17522159.001]
  • [Cites] J Korean Med Sci. 2006 Feb;21(1):160-4 [16479084.001]
  • [Cites] Dev Cell. 2005 Jan;8(1):65-74 [15621530.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):355-6 [12923538.001]
  • [Cites] Mol Cell. 1999 Jan;3(1):1-10 [10024874.001]
  • [Cites] Nat Genet. 1998 May;19(1):47-50 [9590287.001]
  • [Cites] Nature. 1993 Mar 4;362(6415):65-7 [8383297.001]
  • [Cites] Pediatr Nephrol. 2009 Oct;24(10):1921-8 [19190937.001]
  • (PMID = 21189947.001).
  • [ISSN] 2092-7258
  • [Journal-full-title] Korean journal of pediatrics
  • [ISO-abbreviation] Korean J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3004483
  • [Keywords] NOTNLM ; Congenital anomalies / Development / Kidney / Urinary tract
  •  go-up   go-down


31. Colović R, Colović N, Grubor N, Radak V, Micev M, Stojković M: [Bilateral angiomyolipoma of the kidney in patient with tuberous sclerosis]. Srp Arh Celok Lek; 2005 Sep-Oct;133(9-10):433-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral angiomyolipoma of the kidney in patient with tuberous sclerosis].
  • Angiomyolipomas are relatively frequent tumours of the kidney.
  • It is believed that about 10 million people worldwide have such a tumour.
  • Due to the benign nature of angiomyolipomas, surgical treatment and embolisation of the tumours are generally not recommended, unless renal function is endangered, the symptoms are severe, or the kidney in question becomes completely dysfunctional.
  • We present a 24-year-old woman with tuberous sclerosis in whom bilateral kidney tumours were diagnosed 7 years earlier and in whom we carried out a left nephrectomy of a 5300 gram angiomyolipoma, which caused pain and complete loss of function.
  • Although tumourous, the right kidney was functional, so it was left untouched.
  • After an uneventful recovery, a close follow-up was recommended, as well as HLA typing, as it is highly probable that the right kidney will gradually become inadequate or completely dysfunctional, so that haemodialysis and/or kidney transplantation along with nephrectomy will become necessary.
  • [MeSH-major] Angiomyolipoma / complications. Kidney Neoplasms / complications. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640189.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


32. Shah SV, Rajapurkar MM: The role of labile iron in kidney disease and treatment with chelation. Hemoglobin; 2009;33(5):378-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of labile iron in kidney disease and treatment with chelation.
  • There are two major forms of kidney disease: acute renal failure [also referred to as acute kidney injury (AKI)] and chronic kidney disease (CKD).
  • Acute renal failure is an abrupt loss of kidney function within 48 h, whereas CKD is a loss of kidney function greater than 3 months.
  • There is a large amount of experimental evidence for an increase of labile iron in a wide variety of models of kidney disease.
  • These observations suggest that iron chelators may provide a new modality of prevention and treatment of kidney disease.
  • [MeSH-major] Acute Kidney Injury / drug therapy. Acute Kidney Injury / metabolism. Iron / metabolism. Iron Chelating Agents / therapeutic use. Kidney Diseases / drug therapy. Kidney Diseases / metabolism

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821781.001).
  • [ISSN] 1532-432X
  • [Journal-full-title] Hemoglobin
  • [ISO-abbreviation] Hemoglobin
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron Chelating Agents; E1UOL152H7 / Iron
  •  go-up   go-down


33. Palmer BF: Hypertension management in patients with chronic kidney disease. Curr Hypertens Rep; 2008 Oct;10(5):367-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertension management in patients with chronic kidney disease.
  • Hypertension is one of the major risk factors for the development and progression of chronic kidney disease.
  • The loss of renal function leads to impaired renal autoregulation and renders the kidney vulnerable to the damaging effects of uncontrolled hypertension.
  • Mounting evidence indicates that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers slow the progression of chronic kidney disease through effects beyond lowering blood pressure.
  • Studies are needed to determine whether high doses of the single agent or combination therapy is most effective in providing renal protection.
  • Urinary protein excretion is a useful tool for monitoring and titrating therapy to maximize renal protection.
  • Changes in the serum creatinine concentration and hyperkalemia are complications of antihypertensive therapy in patients with chronic kidney disease that can be successfully managed to allow continued use of renin-angiotensin blockade.
  • [MeSH-major] Hypertension / prevention & control. Renal Insufficiency, Chronic / etiology. Renal Insufficiency, Chronic / prevention & control

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Chronic Kidney Disease.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 1999 Aug;34(2):308-14 [10430979.001]
  • [Cites] Nephrol Dial Transplant. 1998 Jul;13(7):1682-5 [9681711.001]
  • [Cites] Curr Opin Pharmacol. 2008 Apr;8(2):120-6 [18308634.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] Kidney Int. 2008 Apr;73(8):963-70 [18272959.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):117-24 [12531578.001]
  • [Cites] Kidney Int. 2006 Sep;70(6):1000-7 [16850026.001]
  • [Cites] Curr Hypertens Rep. 2007 Nov;9(5):393-402 [18177587.001]
  • [Cites] Am J Nephrol. 2006;26(3):268-75 [16763384.001]
  • [Cites] Kidney Int. 2008 Jun;73(12):1419-25 [18337712.001]
  • [Cites] Ann Intern Med. 1995 Nov 15;123(10):754-62 [7574193.001]
  • [Cites] Am J Kidney Dis. 1993 Jul;22(1):188-95 [8322782.001]
  • [Cites] J Am Soc Nephrol. 2003 Nov;14(11):2902-7 [14569100.001]
  • [Cites] Ann Intern Med. 1996 Aug 1;125(3):201-4 [8686978.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):960-6 [17301190.001]
  • [Cites] Ann Intern Med. 2003 Aug 19;139(4):244-52 [12965979.001]
  • [Cites] Kidney Int. 2007 Oct;72 (7):879-85 [17667984.001]
  • [Cites] J Am Soc Nephrol. 2003 Sep;14(9):2352-7 [12937313.001]
  • [Cites] Arch Intern Med. 2005 Apr 25;165(8):947-53 [15851648.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):131-40 [16407508.001]
  • [Cites] Diabetes Care. 2007 Jun;30(6):1577-8 [17389334.001]
  • [Cites] Am J Kidney Dis. 2007 Jan;49(1):12-26 [17185142.001]
  • [Cites] Am J Kidney Dis. 2008 Feb;51(2):199-211 [18215698.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Sep;1(5):1054-65 [17699327.001]
  • [Cites] J Am Soc Nephrol. 2005 Feb;16(2):474-81 [15615822.001]
  • [Cites] Kidney Int. 2004 Jun;65(6):1991-2002 [15149313.001]
  • [Cites] N Engl J Med. 2004 Sep 23;351(13):1296-305 [15385656.001]
  • [Cites] Am J Nephrol. 2007;27(3):287-93 [17457028.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):585-92 [15295051.001]
  • [Cites] N Engl J Med. 2002 Oct 17;347(16):1256-61 [12393824.001]
  • [Cites] J Am Soc Nephrol. 2008 Apr;19(4):743-8 [18235083.001]
  • [Cites] Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290 [15114537.001]
  • [Cites] Ann Intern Med. 2008 Jan 1;148(1):30-48 [17984482.001]
  • [Cites] Ann Intern Med. 2008 Jan 1;148(1):16-29 [17984484.001]
  • [Cites] Kidney Int. 2007 Feb;71(3):188-90 [17252027.001]
  • [Cites] Am J Med Sci. 2004 Dec;328(6):330-43 [15599329.001]
  • [Cites] Hypertension. 2001 Dec 1;38(6):E28-32 [11751742.001]
  • [Cites] Am J Nephrol. 2008;28(3):381-90 [18063856.001]
  • [Cites] Am J Kidney Dis. 2006 Jul;48(1):8-20 [16797382.001]
  • [Cites] Am J Med Sci. 2001 Jun;321(6):388-400 [11417753.001]
  • (PMID = 18775113.001).
  • [ISSN] 1534-3111
  • [Journal-full-title] Current hypertension reports
  • [ISO-abbreviation] Curr. Hypertens. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; EC 3.4.23.15 / Renin
  • [Number-of-references] 40
  •  go-up   go-down


34. Wołyniec W, Zdrojewski Z, Rutkowski B: [Metabolic acidosis after kidney transplantation]. Przegl Lek; 2005;62(1):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metabolic acidosis after kidney transplantation].
  • Metabolic acidosis is a common complication in patients after kidney transplantation.
  • It is caused by inability of transplanted kidney to regenerate bicarbonate buffer.
  • Although every type of acidosis may be present in these patients, the most frequent are renal tubular acidosis and uremic acidosis.
  • Ketoacidosis due to a post-transplant diabetes mellitus and bicarbonate loss in patients after simultaneous pancreas/kidney transplantation are rarely observed.
  • The proper diagnosis and appropriate treatment with oral supplements are essential.
  • [MeSH-major] Acidosis, Renal Tubular / metabolism. Kidney Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053226.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Bicarbonates
  • [Number-of-references] 28
  •  go-up   go-down


35. Hinz S, Weikert S, Magheli A, Hoffmann M, Engers R, Miller K, Kempkensteffen C: Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol; 2009 Dec;182(6):2920-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
  • PURPOSE: EZH2 increases the proliferation rate and apoptosis resistance of renal cell carcinoma cell lines.
  • To date its clinical impact on the outcome in patients with renal cell carcinoma is not known.
  • To our knowledge this is the first study of the association of EZH2 expression with histopathological features and disease outcomes in a large cohort of patients who underwent surgery for renal cell carcinoma.
  • MATERIALS AND METHODS: Real-time reverse transcriptase-polymerase chain reaction was done to quantify EZH2 expression in malignant and adjacent benign renal tissue from a cohort of 119 patients with clear cell renal cell carcinoma.
  • The impact of EZH2 expression on clinicopathological tumor features and outcome was investigated.
  • RESULTS: EZH2 was over expressed in renal cell carcinoma compared to adjacent benign renal parenchyma (median 57.02, range 0 to 368.11 vs 0, range 0 to 280.87, p <0.001).
  • EZH2 expression was not associated with histopathological tumor features and patient characteristics.
  • CONCLUSIONS: These data support a role of EZH2 expression for renal cell carcinoma tumorigenesis rather than tumor progression.
  • Contrary to previous EZH2 findings in cases of various human malignancies, high tumor EZH2 levels appear to indicate less aggressive tumor phenotypes with a favorable prognosis in renal cell carcinoma cases.
  • Our findings suggest that EZH2 provides not only a potential therapeutic target, but also a molecular parameter for outcome prediction in patients with renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. DNA-Binding Proteins / biosynthesis. Kidney Neoplasms / metabolism. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846140.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  •  go-up   go-down


36. el-Assmy A, el-Nahas AR, Hekal IA, Badran M, Youssef RF, Sheir KZ: Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney. J Urol; 2008 Jun;179(6):2229-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of extracorporeal shock wave lithotripsy on renal function: our experience with 156 patients with solitary kidney.
  • PURPOSE: We studied the long-term impact of shock wave lithotripsy on renal function, stone recurrence and hypertension in patients with a solitary kidney.
  • Patients with a solitary kidney provide a unique opportunity to evaluate any clinically significant change in renal function.
  • MATERIALS AND METHODS: We retrospectively reviewed the records of 156 patients with stones in a solitary kidney treated with shock wave lithotripsy monotherapy.
  • Serum creatinine, systolic and diastolic blood pressure, new onset hypertension, calculated glomerular filtration rate, and kidney morphology were determined before and after treatment, and compared by chi-square, paired and unpaired t tests.
  • Renal obstruction caused by steinstrasse after shock wave lithotripsy occurred in 14 (8.9%) patients.
  • CONCLUSIONS: The demonstrated effectiveness, small number of complications at short-term followup, insignificant effect on renal function, blood pressure and relatively small number of recurrences at the long-term followup confirm that shock wave lithotripsy is not only effective but is also safe in the long run.
  • [MeSH-major] Kidney / abnormalities. Kidney / physiopathology. Kidney Calculi / physiopathology. Kidney Calculi / therapy. Kidney Failure, Chronic

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423733.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Brown CT, Kooiman G, Sharma DM, Poulsen J, Grange P: Scarless single-port laparoscopic pelvic kidney nephrectomy. J Laparoendosc Adv Surg Tech A; 2010 Nov;20(9):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scarless single-port laparoscopic pelvic kidney nephrectomy.
  • INTRODUCTION: We report the first pelvic kidney removal through the umbilicus using a scarless pure single-port technique in a young woman.
  • PATIENTS AND METHODS: A 27-year-old woman presented with uro-sepsis and acute renal failure secondary to a dilated, chronically infected, nonfunctioning left-sided pelvic kidney with ureteropelvic obstruction causing an obstruction to the right kidney.
  • Definitive treatment involved removal of the diseased pelvic kidney through the umbilicus via a single-port access device (TriPor™; Olympus).
  • [MeSH-major] Acute Kidney Injury / surgery. Kidney Pelvis / surgery. Laparoscopy / methods. Nephrectomy / methods. Ureteral Obstruction / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20874248.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Cassuto JR, Reese PP, Sonnad S, Bloom RD, Levine MH, Olthoff KM, Shaked A, Naji A, Abt P: Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients. Am J Transplant; 2010 Nov;10(11):2502-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wait list death and survival benefit of kidney transplantation among nonrenal transplant recipients.
  • The disparity between the number of patients waiting for kidney transplantation and the limited supply of kidney allografts has renewed interest in the benefit from kidney transplantation experienced by different groups.
  • This study evaluated kidney transplant survival benefit in prior nonrenal transplant recipients (kidney after liver, KALi; lung, KALu; heart, KAH) compared to primary isolated (KA1) or repeat isolated kidney (KA2) transplant.
  • Following kidney transplant, patient survival was greatest for KA1, similar among KA2, KALi, KAH, and inferior for KALu.
  • Compared to the entire wait list, renal transplantation was associated with a survival benefit among all groups except KALu (p = 0.017; HR = 1.61; CI = 1.09-2.38), where posttransplant survival was inferior to the wait list population.
  • Recipients of KA1 kidney transplantation have the greatest posttransplant survival and compared to the overall kidney wait list, the greatest survival benefit.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 The Authors Journal compilation©2010 The American Society of Transplantation and the American Society of Transplant Surgeons.
  • [Cites] J Am Soc Nephrol. 2000 May;11(5):951-7 [10770975.001]
  • [Cites] Am J Transplant. 2009 Jul;9(7):1489-90 [19519815.001]
  • [Cites] Surgery. 2001 Sep;130(3):457-62 [11562670.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):555-62 [12353942.001]
  • [Cites] N Engl J Med. 2003 Sep 4;349(10):931-40 [12954741.001]
  • [Cites] N Engl J Med. 1984 Sep 13;311(11):699-705 [6382005.001]
  • [Cites] JAMA. 1993 Nov 24;270(20):2469-74 [8230624.001]
  • [Cites] Kidney Int. 1996 Oct;50(4):1089-100 [8887265.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1651-9 [9884254.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2726-33 [16333008.001]
  • [Cites] Am J Transplant. 2006;6(5 Pt 2):1153-69 [16613593.001]
  • [Cites] Transplantation. 2006 Sep 15;82(5):669-74 [16969291.001]
  • [Cites] Am J Transplant. 2007 Feb;7(2):461-5 [17283490.001]
  • [Cites] Am J Transplant. 2007;7(5 Pt 2):1424-33 [17428290.001]
  • [Cites] Am J Transplant. 2007 May;7(5):1140-7 [17331109.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Jul;1(4):832-6 [17699294.001]
  • [Cites] J Heart Lung Transplant. 2008 Feb;27(2):217-21 [18267230.001]
  • [Cites] Transplantation. 2008 May 15;85(9):1277-80 [18475183.001]
  • [Cites] Am J Transplant. 2009 Mar;9(3):578-85 [19260837.001]
  • [Cites] Nephrol Dial Transplant. 2009 May;24(5):1655-62 [19168463.001]
  • [Cites] Am J Transplant. 2009 Jul;9(7):1519-22 [19656142.001]
  • [Cites] Am J Transplant. 2009 Jul;9(7):1528-32 [19656144.001]
  • [Cites] Am J Transplant. 2009 Jul;9(7):1507-12 [19392985.001]
  • [Cites] Am J Transplant. 2009 Jul;9(7):1501-6 [19519807.001]
  • [Cites] J Am Coll Cardiol. 2001 Sep;38(3):705-11 [11527621.001]
  • (PMID = 20977641.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK078688; United States / NIDDK NIH HHS / DK / K23 DK078688-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS235283; NLM/ PMC2966021
  •  go-up   go-down


39. Jung JY, Song JH, Li C, Yang CW, Kang TC, Won MH, Jeong YG, Han KH, Choi KB, Lee SH, Kim J: Expression of epidermal growth factor in the developing rat kidney. Am J Physiol Renal Physiol; 2005 Jan;288(1):F227-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor in the developing rat kidney.
  • Epidermal growth factor (EGF) is important in mammalian renal development.
  • In our study, we investigated the detailed distribution and the time of the first appearance of EGF in developing rat kidney.
  • Kidneys from embryonic 18 (E18)- and 20-day-old (E20) fetuses, postnatal 1 (P1)-, 3 (P3)-, 7 (P7)-, 14 (P14)-, and 21-day-old (P21) pups, and adults were processed for immunohistochemistry and electronmicroscopy.
  • In adult rat kidney, EGF immunoreactivity was found in distal tubule including the thick ascending limb (TAL) and portion 1 of distal convoluted tubule (DCT1), whereas no EGF immunoreactivity was seen in portion 2 of distal convoluted tubule (DCT2) and connecting tubule.
  • In developing kidney, EGF-positive cells first appeared at P3 and were localized in the middle portion of the differentiating TAL of the corticomedullary junction.
  • However, EGF-positive and EGF-negative cells were in the TAL in developing rat kidney.
  • Our results suggest that the expression of EGF in developing kidney plays an important role in the regulation of growth and differentiation of the loop of Henle during kidney development and that this may act in the paracrine mode.
  • [MeSH-major] Epidermal Growth Factor / biosynthesis. Gene Expression Regulation, Developmental / physiology. Kidney / growth & development

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15353402.001).
  • [ISSN] 1931-857X
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


41. Ossareh S, Shooshtarizadeh T, Naseem S: An unusual case of posttransplant osteoid osteoma. Exp Clin Transplant; 2009 Jun;7(2):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplant tumors are one of the important long-term complications of renal transplant.
  • However, aside from noninvasive Kaposi sarcomas, increased production of benign tumors has not been observed after renal transplantation, and to our knowledge, no cases of posttransplant osteoid osteoma have been reported so far.
  • Osteoid osteoma is a common, benign, bone neoplasm that occurs typically in the long bones and presents with severe, intractable pain.
  • Here, we present a 49-year-old man, who presented with increasing bone pain in the right upper arm, 7 months after a renal transplant.
  • Despite an initial normal right humerus radiograph, a raised subperiosteal tumor was diagnosed in the medial border of the right humerus a few months later.
  • The patient's pain, which had been resistant to most analgesics, completely disappeared after surgery, and he is currently devoid of any lesions, 9 months after excision of the tumor.
  • [MeSH-major] Bone Neoplasms / radiography. Humerus / radiography. Kidney Transplantation / adverse effects. Osteoma, Osteoid / radiography

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715521.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


42. Pascual J, Galeano C, Royuela A, Zamora J: A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation; 2010 Aug 27;90(4):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation.
  • BACKGROUND: Steroid withdrawal (SW) after the first posttransplant months in patients receiving a kidney transplant has been recently discouraged in clinical guidelines.
  • METHODS: A systematic review and meta-analysis of randomized controlled trials assessing SW (beyond the second week after kidney transplantation) was performed.
  • CONCLUSIONS: SW after 3 to 6 months of kidney transplantation is associated with increased rates of acute rejection only if CsA is used but not with tacrolimus.
  • [MeSH-major] Adrenal Cortex Hormones / administration & dosage. Kidney Transplantation / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transplantation. 2010 Aug 27;90(4):350-2 [20548264.001]
  • [CommentIn] Transplantation. 2011 Mar 15;91(5):e27-8 [21336084.001]
  • [CommentIn] Transplantation. 2011 Mar 15;91(5):e25; author reply e26-7 [21336081.001]
  • (PMID = 20574419.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Number-of-references] 23
  •  go-up   go-down


43. McKinney CA, Geiger JD, Castle VP, Ruiz RE, Strouse PJ: Aggressive hepatic angiomyolipoma in a child. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiomyolipoma is a tumor of the kidney and, more rarely, the liver, which histologically consists of smooth muscle cells, adipose cells, and abnormal blood vessels in varying proportions.
  • This tumor is generally benign and resection is curative, but here the authors present the case of a 14-year-old girl with an unusual primary hepatic angiomyolipoma that recurred following resection and behaved aggressively.
  • [MeSH-major] Angiomyolipoma / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770828.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Saha SA, Tuttle KR: Influence of glycemic control on the development of diabetic cardiovascular and kidney disease. Cardiol Clin; 2010 Aug;28(3):497-516
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
  • Among the microvascular complications of diabetes, diabetic kidney disease is the most common.
  • This article discusses the various drug classes used to treat diabetes mellitus, and reviews the current clinical evidence linking glycemic control using these drug classes on diabetic kidney and cardiovascular disease.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • Hazardous Substances Data Bank. Acarbose .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20621253.001).
  • [ISSN] 1558-2264
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biguanides; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Sulfonylurea Compounds; 0 / Thiazolidinediones; T58MSI464G / Acarbose
  •  go-up   go-down


45. Stratta RJ, Sundberg AK, Farney AC, Rohr MS, Hartmann EL, Adams PL: Successful simultaneous kidney-pancreas transplantation from extreme donors. Transplant Proc; 2005 Oct;37(8):3535-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful simultaneous kidney-pancreas transplantation from extreme donors.
  • RESULTS: From January 2002 through January 2005, we performed 40 simultaneous kidney-pancreas transplants (SKPT) with Thymoglobulin induction, including 9 (22.5%) from EX and 31 from CONV DDs.
  • With a mean follow-up of 16.8 months in the EX DD group, patient and kidney graft survival rates are both 100%, and the pancreas graft survival rate is 89%.
  • With a mean follow-up of 21.7 months in the CONV DD group, patient and kidney graft survival rates are both 93.5% and the pancreas graft survival rate is 77.4%.
  • All patients with surviving grafts exhibited good initial (1 case of delayed kidney graft function in a CONV DD) and stable long-term kidney and pancreas graft function.
  • [MeSH-major] Antilymphocyte Serum / therapeutic use. Kidney Transplantation / physiology. Pancreas Transplantation / physiology. Tissue Donors / statistics & numerical data


46. Ix JH, De Boer IH, Peralta CA, Adeney KL, Duprez DA, Jenny NS, Siscovick DS, Kestenbaum BR: Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol; 2009 Mar;4(3):609-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study examined the cross-sectional associations of serum phosphorus with ankle brachial index (ABI), pulse pressure, and large and small artery elasticity by radial artery waveform analysis among 1370 individuals (440 with moderate chronic kidney disease) who did not have clinical CVD and participated in the Multi-Ethnic Study of Atherosclerosis.
  • Participants with phosphorus levels >4 mg/dl had greater than four-fold risk for high ABI compared with participants with phosphate levels <3 mg/dl (relative risk 4.6; 95% confidence interval 1.6 to 13.2; P = 0.01) after adjustment for demographics, traditional CVD risk factors, and kidney function.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2004 Aug;15(8):2208-18 [15284307.001]
  • [Cites] Circulation. 2004 Feb 17;109(6):733-9 [14970108.001]
  • [Cites] Exp Mol Pathol. 1970 Oct;13(2):172-89 [5470811.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Diabetologia. 1988 Jan;31(1):16-23 [3350219.001]
  • [Cites] Clin Physiol. 1991 Jan;11(1):21-5 [2019075.001]
  • [Cites] Arterioscler Thromb. 1992 Sep;12(9):1008-16 [1356019.001]
  • [Cites] Diabetologia. 1993 Jul;36(7):615-21 [8359578.001]
  • [Cites] Clin Chim Acta. 1996 Feb 9;245(1):73-84 [8646817.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):978-83 [8696962.001]
  • [Cites] Atherosclerosis. 1996 Dec 20;127(2):155-65 [9125305.001]
  • [Cites] Hypertension. 1999 Jun;33(6):1392-8 [10373222.001]
  • [Cites] Am J Hypertens. 2005 Jan;18(1):65-71 [15691619.001]
  • [Cites] Cardiovasc Res. 2005 May 1;66(2):307-17 [15820199.001]
  • [Cites] Circ Res. 2005 Apr 15;96(7):717-22 [15831823.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):932-43 [15731494.001]
  • [Cites] Circulation. 2005 Oct 25;112(17):2627-33 [16246962.001]
  • [Cites] Arch Intern Med. 2007 May 14;167(9):879-85 [17502528.001]
  • [Cites] Vasc Med. 2007 May;12(2):105-12 [17615798.001]
  • [Cites] J Am Soc Nephrol. 2008 Feb;19(2):213-6 [18094365.001]
  • [Cites] Stroke. 2008 Mar;39(3):863-9 [18258843.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):381-7 [19073826.001]
  • [Cites] Circulation. 2006 Jan 24;113(3):388-93 [16432070.001]
  • [Cites] N Engl J Med. 2001 May 24;344(21):1608-21 [11372014.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S34-7 [11576919.001]
  • [Cites] Am J Kidney Dis. 2002 Sep;40(3):472-9 [12200797.001]
  • [Cites] J Hypertens. 2002 Oct;20(10):1987-93 [12359977.001]
  • [Cites] Am J Epidemiol. 2002 Nov 1;156(9):871-81 [12397006.001]
  • [Cites] Diabetes Care. 2003 Jan;26 Suppl 1:S5-20 [12502614.001]
  • [Cites] Nephrol Dial Transplant. 2003 Sep;18(9):1731-40 [12937218.001]
  • [Cites] J Am Coll Cardiol. 2004 Aug 4;44(3):618-23 [15358030.001]
  • (PMID = 19211667.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / N01HC95169; United States / NHLBI NIH HHS / HC / N01-HC-95165; United States / NHLBI NIH HHS / HC / N01-HC-95169; United States / NHLBI NIH HHS / HL / N01HC95165; United States / NHLBI NIH HHS / HL / N01HC95159
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 27YLU75U4W / Phosphorus
  • [Other-IDs] NLM/ PMC2653665
  •  go-up   go-down


47. Berger A, Preiser W, Kachel HG, Stürmer M, Doerr HW: HBV reactivation after kidney transplantation. J Clin Virol; 2005 Feb;32(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HBV reactivation after kidney transplantation.
  • In this study, we reviewed the virologic laboratory records from kidney recipients.
  • Out of 1512 patients, 228 had been diagnosed with resolved HBV infection (anti-HBc positive, HBsAg negative) but normal liver enzyme levels prior to kidney transplantation.
  • Reappearance of HBsAg after kidney transplantation was observed in two (0.9%) of those patients, which may be attributed to reactivation of a latent infection or to a new HBV infection.
  • Periodic follow-up of HBV serology for early diagnosis of reactivation is highly recommended in transplant recipients.
  • [MeSH-major] Hepatitis B / virology. Hepatitis B Surface Antigens / blood. Hepatitis B virus / physiology. Kidney Transplantation / adverse effects. Virus Activation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15653420.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens
  •  go-up   go-down


48. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G: Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant; 2006 Oct;6(10):2418-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamics of rituximab in kidney allotransplantation.
  • The anti-CD20 antibody rituximab has recently gained interest as a B-cell depleting agent in renal transplantation.
  • However, little is known about the pharmacodynamics of rituximab in renal transplant recipients.
  • We have therefore studied the effect of single-dose rituximab in combination with conventional triple immunosuppressive therapy on the B-cell population in peripheral blood as well as in tissues.
  • A total of 49 renal transplant recipients received single-dose rituximab, as induction therapy (n = 36) or as anti-rejection therapy (n = 13).
  • We counted B cells in peripheral blood and performed immunohistochemical staining on lymph nodes and kidney transplant tissue samples to assess the prevalence of B cells.
  • The immunohistochemical staining showed a complete elimination of B cells in kidney tissue and a reduction of B cells in lymph nodes.
  • In conclusion, single-dose rituximab in kidney transplant recipients evokes a long-term elimination of B cells in peripheral blood as well as within the kidney transplant.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Graft Rejection / drug therapy. Immunologic Factors / pharmacokinetics. Kidney Transplantation / pathology

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925569.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00255593
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


49. Montagner J, Michelon T, Fontanelle B, Oliveira A, Silveira J, Schroeder R, Neumann J, Keitel E, Alexandre CO: BKV-infection in kidney graft dysfunction. Braz J Infect Dis; 2010 Mar-Apr;14(2):170-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BKV-infection in kidney graft dysfunction.
  • INTRODUCTION: BKV nephropathy (BKN) causes kidney graft loss, whose specific diagnosis is invasive and might be predicted by the early detection of active viral infection.
  • OBJECTIVE: Determine the BKV-infection prevalence in late kidney graft dysfunction by urinary decoy cell (DC) and viral DNA detection in urine (viruria) and blood (viremia; active infection).
  • METHODS: Kidney recipients with >1 month follow-up and creatinine >1.5 mg/dL and/or recent increasing >20% (n = 120) had their urine and blood tested for BKV by semi-nested PCR, DC searching, and graft biopsy.
  • Diagnosis efficacy of DC and viruria were compared to viremia.
  • Intense viruria was the single predictive test for active infection (3+; LR = 2.8).1,6-4,9 CONCLUSION: DC, BKV-viruria and -viremia are commun findings under late kidney graft dysfunction.
  • [MeSH-major] BK Virus / isolation & purification. Kidney Transplantation / adverse effects. Polyomavirus Infections / diagnosis. Primary Graft Dysfunction / virology. Tumor Virus Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20563444.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


50. Szeto CC, Kwan BC, Lai KB, Lai FM, Chow KM, Wang G, Luk CC, Li PK: Urinary expression of kidney injury markers in renal transplant recipients. Clin J Am Soc Nephrol; 2010 Dec;5(12):2329-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary expression of kidney injury markers in renal transplant recipients.
  • BACKGROUND AND OBJECTIVES: The outcome of renal transplantation after an episode of acute rejection is difficult to predict, even with an allograft biopsy.
  • We examined whether urinary expression of specific biomarker mRNA could be used as a noninvasive prognostic marker in kidney transplant recipients.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 63 kidney transplant recipients who require graft biopsy because of progressive worsening of kidney function.
  • The mRNA of neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 (KIM-1), IL-18, surfactant protein-C, and S100 calcium-binding proteins A8 and A9 in urinary sediment were quantified.
  • After followed for an average of 39.7 ± 21.1 months, the rate of renal function decline significantly correlated with urinary KIM-1 expression (r = -0.434, P = 0.0004) but not other target genes.
  • CONCLUSIONS: In kidney allograft recipients, urinary KIM-1 expression provides prognostic information in relation to the rate of renal function decline, irrespective of the kidney pathology.
  • [MeSH-major] Acute Kidney Injury / urine. Biomarkers / urine. Kidney Transplantation

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1999 Nov;56(5):1920-7 [10571803.001]
  • [Cites] Transplantation. 1999 Nov 27;68(10):1578-82 [10589958.001]
  • [Cites] N Engl J Med. 2000 Mar 2;342(9):605-12 [10699159.001]
  • [Cites] Kidney Int. 2000 Nov;58(5):2206-14 [11044243.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):947-54 [11274620.001]
  • [Cites] Transplantation. 2001 Sep 15;72(5):948-53 [11571464.001]
  • [Cites] Kidney Int. 2002 Feb;61(2):686-96 [11849412.001]
  • [Cites] Transplantation. 2002 Feb 27;73(4):573-9 [11889433.001]
  • [Cites] J Am Soc Nephrol. 2002 Jul;13(7):1961-72 [12089394.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1125-35 [12234282.001]
  • [Cites] Nephrol Dial Transplant. 2002 Dec;17(12):2099-107 [12454219.001]
  • [Cites] Am J Transplant. 2003 Jan;3(1):17-22 [12492705.001]
  • [Cites] Transplantation. 2003 Apr 27;75(8):1323-30 [12717224.001]
  • [Cites] N Engl J Med. 2003 Jul 10;349(2):125-38 [12853585.001]
  • [Cites] Am J Transplant. 2004 Jun;4(6):853-62 [15147418.001]
  • [Cites] Immunol Rev. 1993 Aug;134:33-81 [8225374.001]
  • [Cites] Transplantation. 1995 May 15;59(9):1280-5 [7762062.001]
  • [Cites] Transplantation. 1995 Jun 27;59(12):1683-9 [7604438.001]
  • [Cites] Kidney Int. 1996 Feb;49(2):518-24 [8821839.001]
  • [Cites] J Am Soc Nephrol. 1999 Aug;10(8):1806-14 [10446950.001]
  • [Cites] Nephrol Dial Transplant. 2005 Jan;20(1):105-13 [15561743.001]
  • [Cites] J Am Soc Nephrol. 2005 Dec;16(12):3771-86 [16251238.001]
  • [Cites] N Engl J Med. 2005 Dec 1;353(22):2342-51 [16319383.001]
  • [Cites] Am J Kidney Dis. 2006 Apr;47(4):578-86 [16564935.001]
  • [Cites] Nat Clin Pract Nephrol. 2006 Mar;2(3):116-7 [16932404.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):44-8 [16754628.001]
  • [Cites] Am J Transplant. 2007 Mar;7(3):518-26 [17352710.001]
  • [Cites] Nephrology (Carlton). 2007 Oct;12(5):494-9 [17803474.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2008 Mar;17(2):127-32 [18277143.001]
  • [Cites] Nat Clin Pract Nephrol. 2008 Mar;4(3):154-65 [18227821.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Mar;3(2):481-90 [18256377.001]
  • [Cites] Kidney Int. 2008 Apr;73(7):863-9 [18059454.001]
  • [Cites] Kidney Int. 2008 May;73(9):1008-16 [18094679.001]
  • [Cites] Am J Kidney Dis. 2008 Sep;52(3):595-605 [18725016.001]
  • [Cites] Nephrol Dial Transplant. 2009 Nov;24(11):3265-8 [19318357.001]
  • [Cites] J Am Soc Nephrol. 2010 Jan;21(1):189-97 [19762491.001]
  • [CommentIn] Clin J Am Soc Nephrol. 2010 Dec;5(12):2141-3 [21115630.001]
  • (PMID = 20671224.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers; 0 / Calgranulin A; 0 / HAVCR1 protein, human; 0 / Interleukin-18; 0 / LCN2 protein, human; 0 / Lipocalins; 0 / Membrane Glycoproteins; 0 / Proto-Oncogene Proteins; 0 / Pulmonary Surfactant-Associated Protein C; 0 / RNA, Messenger; 0 / Receptors, Virus; 0 / SFTPC protein, human
  • [Other-IDs] NLM/ PMC2994096
  •  go-up   go-down


51. Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, Gattegno B, Thibault P, Doublet JD: Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int; 2006 Aug;98(2):298-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma of native kidney in renal transplant recipients.
  • OBJECTIVE: To evaluate the prevalence, prognosis and possible risk factors of renal cell carcinoma (RCC) of the native kidney in renal transplant recipients.
  • PATIENTS AND METHODS: We retrospectively re-examined the follow-up data of 373 consecutive renal transplant recipients at our institution between August 1993 and September 2004.
  • We collected the data of all de novo RCC of the native kidney in the current analysis.
  • RESULTS: Of the 373 patients examined, 12 tumours of the native kidney were diagnosed in 10 individuals.
  • The mean ages at transplantation and diagnosis were 33 and 45.8 years, respectively.
  • Among the renal ultrasonograms there were two false-negative results.
  • The mean tumour size was 21 mm.
  • Among the 12 kidney malignancies, there were five conventional RCCs and seven papillary RCCs.
  • One of the 10 patients died, from progression of metastases 6 years after diagnosis.
  • One patient had a local recurrence 2 years after diagnosis.
  • CONCLUSIONS: There appears to be a greater risk of RCC of the native kidney in patients with end-stage renal disease.
  • The present results suggest that an annual examination of the native kidney before and after renal transplantation is essential.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Failure, Chronic / surgery. Kidney Neoplasms / etiology. Kidney Transplantation. Postoperative Complications / etiology


52. Chang MY, Ong AC: Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol; 2008;108(1):p1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment.
  • Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder affecting 1 in 1,000 people in the general population and accounts for up to 10% of all patients on renal replacement therapy.
  • Numerous fluid-filled epithelial cysts arise from different nephron segments as spherical dilatations or small out-pouchings, enlarge progressively and eventually become disconnected from the rest of the renal tubule.
  • The development of cysts is accompanied by destruction of the renal parenchyma, interstitial fibrosis, cellular infiltration and loss of functional nephrons.
  • ADPKD is not only a kidney disease but also a systemic disorder associated with intracranial arterial aneurysms, cardiac valvular defects, colonic diverticulosis and cyst formation in other organs such as the liver, spleen and pancreas.
  • The identification of PKD1 and PKD2 together with the drive to elucidate the functions of their encoded proteins, polycystin-1 (PC1) and polycystin-2 (PC2), has led to an explosion of clinical and scientific interest in this common disorder.
  • [MeSH-major] Polycystic Kidney, Autosomal Dominant / etiology. Polycystic Kidney, Autosomal Dominant / therapy


53. Stasević Z, Gorgieva GS, Vasić S, Ristić S, Djukanović L, Lezaić V: High prevalence of kidney disease in two rural communities in Kosovo and Metohia. Ren Fail; 2010 Jun;32(5):541-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of kidney disease in two rural communities in Kosovo and Metohia.
  • A systematic survey was carried out in an enclave in Kosovo and Metohia, with the aim of assessing the prevalence of kidney diseases.
  • Persons with any detected disorder indicating kidney disease were invited for additional examination of kidney function.
  • Glomerular filtration rate (Modification of Diet in Renal Disease (MDRD) formula) below 60 mL/min/1.73 m(2) was found in 5.2% of subjects.
  • Kidney ultrasound examination detected reduced length of right and left kidneys in 38 and 24 persons, respectively.
  • Cysts were also a frequent finding, but polycystic kidney, hydronephrosis, and kidney stones were found in about 2% each.
  • The analysis of data obtained by the present examination and available medical documentation revealed kidney and urinary tract diseases in 98 persons: 52 patients with already known disease and 46 patients detected in the survey.
  • Out of them in 22 patients diagnosis of kidney disease could not be established during the survey but laboratory analyses indicated that they might suffer from tubulointerstitial disease: 14 had tubular dysfunctions, 8 of them low-grade proteinuria, and 12 had a positive family history for kidney disease.
  • In the enclave of Velika Hoca and Orahovac the prevalence of kidney disease was 7.0% indicating that these communities might be placed among those with a high prevalence of kidney disease in Serbia.
  • [MeSH-major] Kidney Diseases / epidemiology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486835.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


54. Sulejmanagić H, Sulejmanagić N, Prohić S, Secić S, Miseljić S: Dental treatment of patients with kidney diseases-review. Bosn J Basic Med Sci; 2005 Feb;5(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dental treatment of patients with kidney diseases-review.
  • In their practice every dentist is brought into a situation to treat patients with grossly impaired kidney function.
  • Kidney diseases, whether acute or acquired, imply a number of body dysfunctions such as prolonged bleeding, high blood pressure, infection tendency etc. which, in turn, pose a threat involving serious complications in cases of dental interventions in these patients.
  • The aim of this article is to provide a review of current dental practice in patients with kidney disease.
  • This implies dental intervention and preparations of patients with chronic renal disease, nephritic syndrome, patients on dialysis, and patients with kidney transplants.
  • Certainly, cooperation between the dentist and nephrologist is an imperative for the appropriate dental treatment of patients with grossly impaired renal function.

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771603.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 12
  •  go-up   go-down


55. Neuhofer W, Pittrow D: Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest; 2009 Jun;39 Suppl 2:50-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence.
  • In addition to its substantial contribution to normal renal function, a large body of evidence suggests that derangement of the renal ET system is involved in the initiation and progression of chronic kidney disease (CKD) in diabetes, hypertension and glomerulonephritis.
  • Recent literature on the role of the renal ET system in the healthy kidney was reviewed.
  • ET-1 acts primarily as an autocrine or paracrine factor in the kidney.
  • In normal physiology, ET-1 promotes diuresis and natriuresis by local production and action through ET(B) receptors in the renal medulla.
  • [MeSH-major] Endothelin Receptor Antagonists. Endothelin-1 / physiology. Kidney Failure, Chronic / physiopathology

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Clin Invest. 2009 Jul;39(7):630
  • (PMID = 19335747.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Endothelin A Receptor Antagonists; 0 / Endothelin B Receptor Antagonists; 0 / Endothelin Receptor Antagonists; 0 / Endothelin-1; 0 / Receptors, Endothelin
  • [Number-of-references] 125
  • [General-notes] NLM/ Original DateCompleted: 20090407
  •  go-up   go-down


56. Kim YW, Park BS, Ryu CH, Park SJ, Kang SW, Kim YH, Song IS, Shon JH: Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clin Nephrol; 2009 Feb;71(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allopurinol-induced aplastic anemia in a patient with chronic kidney disease.
  • We report an unusual case of aplastic anemia associated with allopurinol therapy for hyperuricemia in a patient with chronic kidney disease.
  • A 37-year-old female patient diagnosed with Stage III chronic kidney disease was admitted with pancytopenia.
  • These results suggested a diagnosis of aplastic anemia.
  • [MeSH-major] Allopurinol / adverse effects. Anemia, Aplastic / chemically induced. Enzyme Inhibitors / adverse effects. Kidney Failure, Chronic / complications


57. Peces R, Peces C, Pérez-Dueñas V, Cuesta-López E, Azorín S, Selgas R: Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease. NDT Plus; 2009 Apr;2(2):133-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease.
  • This is the first report of a case of a reduction in kidney volume and preservation of renal function in a patient with autosomal-dominant polycystic kidney disease (ADPKD) receiving rapamycin.
  • A 42-year-old man with ADPKD and a severe persistent bleeding from his solitary left kidney was successfully treated with tranexamic acid (TXA).
  • He also received low-dose rapamycin for 8 months, and this was associated with a 23.5% reduction in kidney volume, improvement and stabilization of renal function, and normalization of haemoglobin levels.
  • When treatment with rapamycin was interrupted, renal function deteriorated within an 8-month period and haemodialysis (HD) became necessary.
  • Kidney volume increased at once, and life-threatening bleeding prompted a nephrectomy 4 months after the onset of HD.
  • These data suggest that the reduction in kidney volume and preservation of renal function with rapamycin could be the result of the antiangiogenic, antiproliferative effects of rapamycin.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25949309.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4421355
  • [Keywords] NOTNLM ; ADPKD / mTOR / rapamycin / renal function / volume change
  •  go-up   go-down


58. Lee M, Partridge NC: Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens; 2009 Jul;18(4):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid hormone signaling in bone and kidney.
  • PURPOSE OF REVIEW: Parathyroid hormone (PTH) maintains a physiological balance of calcium and phosphate concentrations by binding to its receptor on the plasma membrane of cells in bone and kidney.
  • Here, we will review the recent advancements regarding PTH signaling in bone and kidney.
  • In kidney, sodium-hydrogen exchanger regulatory factor 1, originally known for its role in the retention of NaPi-IIa at the apical membrane, was shown to have multiple roles in PTH signaling, both as a mediator and regulator.
  • SUMMARY: PTH activates a number of different signaling pathways by binding to a single receptor in bone and kidney.
  • [MeSH-major] Bone and Bones / metabolism. Kidney / metabolism. Parathyroid Hormone / physiology. Signal Transduction / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395963.001).
  • [ISSN] 1473-6543
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47420
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 0 / Phosphoproteins; 0 / Receptor, Parathyroid Hormone, Type 1; 0 / Sodium-Hydrogen Antiporter; 0 / sodium-hydrogen exchanger regulatory factor; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.13 / Protein Kinase C; SY7Q814VUP / Calcium
  • [Number-of-references] 58
  •  go-up   go-down


59. Gerosa C, Fanni D, Nemolato S, Locci A, Marinelli V, Cabras T, Messana I, Castagnola M, Monga G, Fanos V, Faa G: Thymosin beta-10 expression in developing human kidney. J Matern Fetal Neonatal Med; 2010 Oct;23 Suppl 3:125-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymosin beta-10 expression in developing human kidney.
  • The report that the Tβ10 gene is expressed at high levels in embryonic human brain as well in human kidney induced us to study Tβ10 reactivity in the preterm kidney in order to verify, at tissue level, the expression of this peptide during renal embryogenesis.
  • To this end, we analyzed, using immunocytochemistry, the expression of Tβ10 in samples of human kidney obtained, at autopsy, from 8 fetuses, 12 preterm infants, ranging from 25 to 36 weeks of gestation and 3 at term newborns.
  • Tβ10 immunoreactivity was detected in 20 out of 22 kidneys examined, and was mainly localized in proximal and distal tubular structures, in the cytoplasm and occasionally in the nuclei of ductal cells.
  • In 13 kidneys, we also observed immunostaining for Tβ10 inside the "comma-shaped bodies" and the "S-shaped bodies" during active glomerulogenesis.
  • Our data show, for the first time, the expression of Tβ10 in the human kidney during the initial phases of its physiological development, mainly restricted in the proximal and the distal tubuli.
  • Further studies are needed in order to better characterize the role of Tβ10 in kidney embryogenesis.
  • [MeSH-major] Kidney / embryology. Kidney / metabolism. Thymosin / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836742.001).
  • [ISSN] 1476-4954
  • [Journal-full-title] The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • [ISO-abbreviation] J. Matern. Fetal. Neonatal. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 61512-21-8 / Thymosin; 87397-91-9 / thymosin beta(10)
  •  go-up   go-down


60. Zukowski M, Bohatyrewicz R, Biernawska J, Kotfis K, Zegan M, Knap R, Janeczek M, Zietek Z: Risk factors for septic complications in kidney transplant recipients. Transplant Proc; 2009 Oct;41(8):3043-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for septic complications in kidney transplant recipients.
  • INTRODUCTION: Septic complications following kidney transplantation are a leading cause of therapeutic failure.
  • An early diagnosis may protect the recipient from the severe consequences of sepsis.
  • We sought to determine the risk factors influencing the occurrence of septic complications among kidney transplant recipients.
  • Recipient data included age, gender, period of prior hemodialysis, panel reactive antibodies, cold ischemia time, and cause of renal insufficiency.
  • The 232 kidney recipients were examined for occurrence of septic complications including septicemia, pneumonia, peritonitis, or graft infection.
  • RESULTS: Kidney transplants from donors with MAP < 70 mm Hg and SVRI < 1200 dyne x s/cm(5) x m(2) showed a significantly higher occurrence of septic complications in recipients (P < .05) where mortality rate was also significantly greater (P < .01).
  • CONCLUSIONS: MAP < 70 mm Hg and SVRI < 1200 dyne x s/cm(5) x m(2) among organ donors predicted greater occurrence of septic complications and increased mortality among kidney transplant recipients.
  • [MeSH-major] Kidney Transplantation / physiology. Sepsis / epidemiology
  • [MeSH-minor] Adolescent. Adult. Blood Pressure / physiology. Brain Death. Cadaver. Cause of Death. Central Venous Pressure / physiology. Child. Female. Heart Rate. Humans. Male. Middle Aged. Renal Dialysis. Risk Factors. Shock, Septic / epidemiology. Tissue Donors. Vascular Resistance. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19857672.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Li L, Okusa MD: Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol; 2010 May;30(3):268-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophages, dendritic cells, and kidney ischemia-reperfusion injury.
  • Dendritic cells and macrophages are critical early initiators of innate immunity in the kidney and orchestrate inflammation subsequent to ischemia-reperfusion injury.
  • They are the most abundant leukocytes present in the kidney, and they represent a heterogeneous population of cells that are capable of inducing sterile inflammation after reperfusion directly through the production of proinflammatory cytokines and other soluble inflammatory mediators or indirectly through activation of effector T lymphocytes and natural killer T cells.
  • In addition, recent studies have indicated that kidney and immune cell micro-RNAs control gene expression and have the ability to regulate the initial inflammatory response to injury.
  • Although dendritic cells and macrophages contribute to both innate and adaptive immunity and to injury and repair, this review focuses on the initial innate response to kidney ischemia-reperfusion injury.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Aug 25;126(4):659-62 [16923387.001]
  • [Cites] Nat Clin Pract Nephrol. 2006 Aug;2(8):432-44 [16932478.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):31-40 [17186029.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):185-94 [17200718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9 [17242365.001]
  • [Cites] J Immunol. 2007 May 1;178(9):5899-911 [17442974.001]
  • [Cites] Science. 2007 Aug 3;317(5838):666-70 [17673663.001]
  • [Cites] Kidney Int. 2007 Dec;72(12):1493-502 [17914353.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jan;294(1):F264-71 [18003857.001]
  • [Cites] Kidney Int. 2008 Jun;73(11):1220-30 [18322542.001]
  • [Cites] Kidney Int. 2008 Jul;74(1):5-7 [18560360.001]
  • [Cites] Nephron Exp Nephrol. 2008;109(4):e102-7 [18802372.001]
  • [Cites] Kidney Int. 2008 Dec;74(12):1526-37 [18843253.001]
  • [Cites] Clin Immunol. 2009 Jan;130(1):41-50 [18922742.001]
  • [Cites] J Cell Physiol. 2009 Mar;218(3):467-72 [19034913.001]
  • [Cites] Kidney Int. 2009 Apr;75(7):689-98 [19129795.001]
  • [Cites] J Clin Invest. 2009 May;119(5):1275-85 [19349686.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2009 Jul;18(4):317-23 [19424061.001]
  • [Cites] Immunology. 2009 Jul;127(3):291-8 [19538248.001]
  • [Cites] Nature. 2009 Jul 30;460(7255):637-41 [19536155.001]
  • [Cites] J Am Soc Nephrol. 2009 Aug;20(8):1744-53 [19497969.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 Oct;297(4):F961-70 [19656911.001]
  • [Cites] J Pathol. 2008 Jan;214(2):161-78 [18161744.001]
  • [Cites] Transplantation. 2000 Mar 15;69(5):959-63 [10755557.001]
  • [Cites] Nephrol Dial Transplant. 2000 Oct;15(10):1562-74 [11007823.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):510-4 [11101873.001]
  • [Cites] Kidney Int. 2001 May;59(5):1626-40 [11318933.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1145-52 [11342578.001]
  • [Cites] J Immunol. 2001 May 15;166(10):6012-8 [11342617.001]
  • [Cites] Kidney Int. 2001 Jun;59(6):2073-83 [11380809.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):1013-20 [11581322.001]
  • [Cites] Annu Rev Immunol. 2002;20:197-216 [11861602.001]
  • [Cites] Science. 2002 Apr 12;296(5566):301-5 [11951032.001]
  • [Cites] Kidney Int. 2002 Jun;61(6):1935-46 [12028434.001]
  • [Cites] Blood. 2003 Jan 1;101(1):143-50 [12393446.001]
  • [Cites] Kidney Int. 2003 Feb;63(2):543-53 [12631119.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4069-76 [12682236.001]
  • [Cites] Immunity. 2003 Jul;19(1):71-82 [12871640.001]
  • [Cites] J Am Soc Nephrol. 2003 Aug;14(8):2199-210 [12874476.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2262-9 [12928370.001]
  • [Cites] J Clin Invest. 2003 Sep;112(6):883-91 [12975473.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14(10):2503-15 [14514728.001]
  • [Cites] J Am Soc Nephrol. 2004 Apr;15(4):854-67 [15034087.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2004 May;13(3):285-90 [15073486.001]
  • [Cites] J Clin Invest. 2004 Jul;114(1):5-14 [15232604.001]
  • [Cites] J Clin Invest. 1981 Sep;68(3):686-98 [7276168.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1983;77(5):620-30 [6362115.001]
  • [Cites] Lab Invest. 1984 Aug;51(2):172-80 [6611452.001]
  • [Cites] Kidney Int. 1984 Sep;26(3):283-93 [6513274.001]
  • [Cites] Am J Physiol. 1985 Jun;248(6 Pt 2):F845-50 [2408488.001]
  • [Cites] Am J Physiol. 1986 Feb;250(2 Pt 2):F357-63 [3946611.001]
  • [Cites] Am J Kidney Dis. 1989 Mar;13(3):253-8 [2493191.001]
  • [Cites] Curr Opin Immunol. 1991 Feb;3(1):65-70 [1711326.001]
  • [Cites] Kidney Int. 1994 Mar;45(3):709-20 [8196273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3942-6 [8632994.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1448-60 [8618585.001]
  • [Cites] J Clin Invest. 1997 Jun 1;99(11):2682-90 [9169498.001]
  • [Cites] Kidney Int. 1997 Jul;52(1):60-70 [9211347.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1199-203 [9276737.001]
  • [Cites] Immunity. 1999 Jan;10(1):29-38 [10023768.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Feb;288(2):F387-98 [15494543.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Apr;288(4):F722-31 [15561971.001]
  • [Cites] Nat Methods. 2005 Jun;2(6):419-26 [15908920.001]
  • [Cites] Nat Rev Immunol. 2005 Dec;5(12):953-64 [16322748.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1198-205 [16369559.001]
  • [Cites] Science. 2006 Jan 6;311(5757):83-7 [16322423.001]
  • [Cites] Nephrol Dial Transplant. 2006 May;21(5):1231-9 [16410269.001]
  • (PMID = 20620671.001).
  • [ISSN] 1558-4488
  • [Journal-full-title] Seminars in nephrology
  • [ISO-abbreviation] Semin. Nephrol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK062324-08; United States / NIDDK NIH HHS / DK / DK062324-07; United States / NIDDK NIH HHS / DK / R01 DK056223-08; United States / NIDDK NIH HHS / DK / R01 DK085259; United States / NIDDK NIH HHS / DK / R01DK56223; United States / NIDDK NIH HHS / DK / R01 DK062324; United States / NIDDK NIH HHS / DK / R01 DK056223; United States / NIDDK NIH HHS / DK / R01DK62324; United States / NIDDK NIH HHS / DK / DK056223-08; United States / NIDDK NIH HHS / DK / R01 DK062324-07; United States / NIDDK NIH HHS / DK / R01 DK062324-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS188223; NLM/ PMC2904394
  •  go-up   go-down


62. Bansal N, Hsu CY: Long-term outcomes of patients with chronic kidney disease. Nat Clin Pract Nephrol; 2008 Oct;4(10):532-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of patients with chronic kidney disease.
  • This Practice Point commentary discusses a recent paper by Menon et al. that described the natural history of a cohort of nondiabetic patients with stage 2-4 chronic kidney disease (CKD) who had been recruited from nephrology practices and screened for entry into the Modification of Diet in Renal Disease (MDRD) trial.
  • Kidney failure was the most common outcome during long-term follow-up among these patients and there was a low competing risk of death, findings in contrast to observations in other cohorts of patients with CKD.
  • Patients with lower glomerular filtration rate and greater proteinuria at baseline were at increased risk for both kidney failure and death, but kidney failure remained more likely than death in all glomerular filtration rate subgroups.
  • Nephrologists should not rely on CKD staging alone to direct management of or risk-stratify patients with CKD, but should also consider the etiology and rate of progression of kidney disease, patient age and cardiovascular disease risk factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Kidney Int. 2008 Jun;73(11):1310-5 [18337713.001]
  • (PMID = 18695707.001).
  • [ISSN] 1745-8331
  • [Journal-full-title] Nature clinical practice. Nephrology
  • [ISO-abbreviation] Nat Clin Pract Nephrol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23 DK088865
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Pecoits-Filho R: Dietary protein intake and kidney disease in Western diet. Contrib Nephrol; 2007;155:102-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary protein intake and kidney disease in Western diet.
  • Components of the diet related to changes in eating habits that characterize the modern Western world are important factors in the increasingly high prevalence of chronic disease, including obesity, diabetes, hypertension and as a consequence, chronic kidney disease.
  • Unfortunately, very few clinical studies focused on diet-based strategies of prevention of kidney disorders.
  • Furthermore, this review will propose that the concept that protein restricted diets decrease the risk of developing kidney disease in the general population is not supported by the scientific literature.
  • Indeed, preliminary studies showing a positive effect of relatively high protein diets on risk factors for chronic kidney disease (particularly on obesity, hypertension and diabetes) point to the need for future studies addressing diets that could prevent the increasingly high prevalence of kidney disease in the Western world.
  • On the other hand, there is a potential role for protein restriction in patients with established kidney disease, particularly in patients with significant decrease in glomerular filtration rate.
  • The exact protective action of protein restriction in patients with established renal disease needs further analysis, taking into account the more broad effects of protein restriction (lower phosphate, acidosis, uric acid) and a more current definition of malnutrition.
  • [MeSH-major] Diet / ethnology. Diet, Protein-Restricted. Dietary Proteins. Kidney Diseases / prevention & control

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Dietary Proteins.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369718.001).
  • [ISSN] 0302-5144
  • [Journal-full-title] Contributions to nephrology
  • [ISO-abbreviation] Contrib Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Dietary Proteins
  • [Number-of-references] 41
  •  go-up   go-down


64. Stratta RJ, Sundberg AK, Rohr MS, Farney AC, Hartmann EL, Roskopf JA, Iskandar SS, Hairston G, Kiger DF, Gautreaux MD, Anderson TK, Adams PL: Optimal use of older donors and recipients in kidney transplantation. Surgery; 2006 Mar;139(3):324-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal use of older donors and recipients in kidney transplantation.
  • BACKGROUND: The aging donor and recipient population have led to new challenges in kidney transplantation.
  • The purpose of this study was to review retrospectively our single center experience in deceased-donor kidney transplantation, with respect to donor and recipient age.
  • METHODS: From October 1, 2001, through February 20, 2004, we performed 144 deceased-donor kidney transplantations, which included 37 procedures (26%) in recipients > or =60 years old and 107 procedures (74%) in recipients 19 to 59 years old.
  • ECD kidneys were used by matching estimated renal functional mass to recipient size (body mass index, <25 kg/m(2)), which included the use of dual kidney transplantations (n = 9).
  • ECD kidney recipients were further selected on the basis of age >40 years and low immunologic risk.
  • In recipients > or =60 years old, 23 recipients (62%) received kidney transplants from ECDs compared with 34 kidney transplants from ECDs (32%; P < .001) in recipients who were <60 years old.
  • Kidney graft survival rates were 84% in both recipient groups.
  • CONCLUSION: By the matching of nephron mass with recipient size and avoiding the use of ECD kidneys in recipients with a high immunologic risk, short-term outcomes that are comparable with standard criteria donor kidneys in younger patients can be achieved with either older donors or recipients, regardless of age.
  • [MeSH-major] Kidney Transplantation. Patient Selection. Tissue Donors


65. Okamoto M, Suzuki T, Fujiki M, Nobori S, Ushigome H, Sakamoto S, Yoshimura N: The consequences for live kidney donors with preexisting glucose intolerance without diabetic complication: analysis at a single Japanese center. Transplantation; 2010 Jun 15;89(11):1391-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The consequences for live kidney donors with preexisting glucose intolerance without diabetic complication: analysis at a single Japanese center.
  • BACKGROUND: Because of lack of deceased donors in Japan, there has been a need to expand the eligibility criteria for live kidney donation.
  • To assess the indications for live kidney donation in glucose intolerance (GI), we analyzed perioperative complications associated with donor nephrectomies performed at our institution and followed up the long-term consequences.
  • METHODS: The 444 live kidney donors were divided into two groups based on the results of the 75-g oral glucose tolerance test: a GI group (n=71) who showed a diabetic (n=27) or impaired glucose tolerance (n=44) pattern, and a non-GI group (n=373) who showed a normal oral glucose tolerance test pattern.
  • Perioperative complications, longterm survival rate, and frequencies of hypertension, diabetes, hyperlipidemia, and renal dysfunction in long term were compared in each group.
  • None of the patients in the diabetes mellitus group had developed severe diabetic complications or end-stage renal disease at a mean follow-up point of 88+/-71 (range, 14-225) months.
  • CONCLUSIONS: Our results suggest that individuals who have GI without diabetic complication may be able to donate their kidney safely with little surgical complication and little major morbidity if strict evaluation is performed before transplant.
  • [MeSH-major] Glucose Intolerance / epidemiology. Kidney Transplantation / physiology. Living Donors. Nephrectomy. Tissue and Organ Procurement / statistics & numerical data


66. Kestenbaum B, Belozeroff V: Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest; 2007 Aug;37(8):607-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mineral metabolism disturbances in patients with chronic kidney disease.
  • BACKGROUND: Kidney disease, especially chronic kidney disease (CKD), is a worldwide public health problem with serious adverse health consequences for affected individuals.
  • Secondary hyperparathyroidism, a disorder characterized by elevated serum parathyroid hormone levels, and alteration of calcium and phosphorus homeostasis are common metabolic complications of CKD that may impact cardiovascular health.
  • RESULTS: Mineral metabolism disturbances begin early during the course of chronic kidney disease, and are associated with cardiovascular disease and mortality in observational studies.
  • Vascular calcification is one plausible mechanism connecting renal-related mineral metabolism with cardiovascular risk.
  • CONCLUSIONS: There exists a potential to improve outcomes for patients with CKD through increased awareness of the Bone Metabolism and Disease guidelines set forth by the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative.
  • [MeSH-major] Calcium / metabolism. Cardiovascular Diseases / etiology. Hyperparathyroidism, Secondary / etiology. Kidney Failure, Chronic / complications. Parathyroid Hormone / secretion. Phosphorus / metabolism
  • [MeSH-minor] Calcinosis / etiology. Female. Humans. Male. Renal Dialysis. Risk Factors. Vitamin D / analogs & derivatives. Vitamin D / blood. Vitamin D / therapeutic use

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635571.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 1406-16-2 / Vitamin D; 27YLU75U4W / Phosphorus; SY7Q814VUP / Calcium
  • [Number-of-references] 137
  •  go-up   go-down


67. Hanratty R, Chonchol M, Miriam Dickinson L, Beaty BL, Estacio RO, Mackenzie TD, Hurley LP, Linas SL, Steiner JF, Havranek EP: Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant; 2010 Mar;25(3):801-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension.
  • BACKGROUND: Little is known about the decline of kidney function in patients with normal kidney function at baseline.
  • Our objectives were to (i) identify predictors of incident chronic kidney disease (CKD) and (ii) to estimate rate of decline in kidney function.
  • Rates of incident CKD or in decline of kidney function did not differ by race or ethnicity in this cohort.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2001 May 14;161(9):1207-16 [11343443.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] Am J Kidney Dis. 2003 Jan;41(1):1-12 [12500213.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):143-9 [12529097.001]
  • [Cites] J Am Soc Nephrol. 2003 Nov;14(11):2902-7 [14569100.001]
  • [Cites] Hypertension. 2003 Dec;42(6):1144-9 [14597644.001]
  • [Cites] JAMA. 2004 Feb 18;291(7):844-50 [14970063.001]
  • [Cites] J Am Geriatr Soc. 1985 Apr;33(4):278-85 [3989190.001]
  • [Cites] Kidney Int. 2006 Jan;69(2):375-82 [16408129.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S98-103 [16565257.001]
  • [Cites] Kidney Int. 2006 Jun;69(12):2155-61 [16531986.001]
  • [Cites] J Am Soc Nephrol. 2006 Oct;17(10):2892-9 [16959827.001]
  • [Cites] Nephrol Dial Transplant. 2007 Jan;22(1):3-5 [17005519.001]
  • [Cites] J Am Soc Nephrol. 2007 Oct;18(10):2749-57 [17855641.001]
  • [Cites] JAMA. 2007 Nov 7;298(17):2038-47 [17986697.001]
  • [Cites] J Health Care Poor Underserved. 2008 May;19(2):452-65 [18469416.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 Sep;3(5):1332-8 [18667734.001]
  • [Cites] J Am Soc Nephrol. 2008 Nov;19(11):2047-51 [18923054.001]
  • [Cites] Arch Intern Med. 2008 Dec 8;168(22):2466-73 [19064831.001]
  • (PMID = 19889870.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL079160; United States / NHLBI NIH HHS / HL / U01 HL079208; United States / NHLBI NIH HHS / HL / 1U01 HL079160; United States / NHLBI NIH HHS / HL / 1U01 HL079208
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2828608
  •  go-up   go-down


68. Cunningham J, Cass A, Anderson K, Snelling P, Devitt J, Preece C, Eris J: Australian nephrologists' attitudes towards living kidney donation. Nephrol Dial Transplant; 2006 May;21(5):1178-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Australian nephrologists' attitudes towards living kidney donation.
  • BACKGROUND: The demand for deceased donor kidneys far outweighs the supply.
  • The rate of living kidney donation (LKD) has been steadily increasing world-wide and is associated with excellent outcomes for the recipient.
  • The vast majority (95%) of respondents indicated that they would recommend it to a suitable donor or would themselves (97%) donate a kidney to an immediate family member.
  • However, fewer than half (43%) would recommend LKD to a potential donor, where their relative's end-stage kidney disease (ESKD) had been attributed to diabetes and where there was a strong family history of diabetes.
  • Meeting the growing demand for kidney transplantation will require an increased supply of both live and deceased donor kidneys.
  • [MeSH-major] Attitude of Health Personnel. Kidney Transplantation / psychology. Living Donors. Tissue and Organ Procurement
  • [MeSH-minor] Adult. Australia. Diabetic Nephropathies / diagnosis. Diabetic Nephropathies / surgery. Female. Health Care Surveys. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Nephrectomy / methods. Nephrology / standards. Nephrology / trends. Practice Patterns, Physicians'. Risk Assessment. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490747.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Editorial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Thomas MC, Atkins RC: Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs; 2006;66(17):2213-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
  • The current pandemic of diabetes mellitus will inevitably be followed by an epidemic of chronic kidney disease.
  • It is anticipated that 25-40% of patients with type 1 diabetes and 5-40% of patients with type 2 diabetes will ultimately develop diabetic kidney disease.
  • Diabetic nephropathy may lead to hypertension through direct actions on renal sodium handling, vascular compliance and vasomotor function.
  • Recent clinical trials also support the utility of blood pressure reduction in the prevention of diabetic kidney disease.
  • In patients with overt nephropathy, blood pressure reduction is associated with reduced urinary albumin excretion and, subsequently, a reduced risk of renal impairment or end stage renal disease.
  • Although there is a clear physiological rationale for blockade of the renin angiotensin system, which is strongly supported by clinical studies, to achieve the optimal lowering of blood pressure, particularly in the setting of established diabetic renal disease, a number of different antihypertensive agents will always be needed.
  • Ultimately, no matter how it is achieved, so long as it is achieved, renal risk can be reduced by agents that lower blood pressure and albuminuria.
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Blood Pressure / drug effects. Diabetes Complications / diagnosis. Diabetes Mellitus / therapy. Diabetic Nephropathies / prevention & control. Hypertension / drug therapy


70. Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ: Long-term consequences of kidney donation. N Engl J Med; 2009 Jan 29;360(5):459-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term consequences of kidney donation.
  • BACKGROUND: The long-term renal consequences of kidney donation by a living donor are attracting increased appropriate interest.
  • The overall evidence suggests that living kidney donors have survival similar to that of nondonors and that their risk of end-stage renal disease (ESRD) is not increased.
  • METHODS: We ascertained the vital status and lifetime risk of ESRD in 3698 kidney donors who donated kidneys during the period from 1963 through 2007; from 2003 through 2007, we also measured the glomerular filtration rate (GFR) and urinary albumin excretion and assessed the prevalence of hypertension, general health status, and quality of life in 255 donors.
  • RESULTS: The survival of kidney donors was similar to that of controls who were matched for age, sex, and race or ethnic group.
  • CONCLUSIONS: Survival and the risk of ESRD in carefully screened kidney donors appear to be similar to those in the general population.
  • [MeSH-major] Health Status. Kidney Failure, Chronic / epidemiology. Kidney Transplantation. Living Donors. Quality of Life

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Transplantation. 2006 Dec 27;82(12):1646-8 [17198252.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1801-10 [17003822.001]
  • [Cites] Transplantation. 2007 Sep 15;84(5):647-9 [17876279.001]
  • [Cites] Ann Intern Med. 2006 Aug 1;145(3):185-96 [16880460.001]
  • [Cites] Am J Transplant. 2006 Jun;6(6):1479-85 [16686774.001]
  • [Cites] J Clin Invest. 1950 May;29(5):496-507 [15415454.001]
  • [Cites] Transplantation. 1997 Oct 15;64(7):976-8 [9381544.001]
  • [Cites] J Am Soc Nephrol. 1995 Aug;6(2):257-63 [7579093.001]
  • [Cites] N Engl J Med. 2001 Nov 1;345(18):1291-7 [11794147.001]
  • [Cites] Transplantation. 2002 Nov 15;74(9):1349-51 [12451277.001]
  • [Cites] Am J Transplant. 2002 Nov;2(10):959-64 [12482149.001]
  • [Cites] JAMA. 1966 Apr 25;196(4):322-4 [5952198.001]
  • [Cites] Am J Pathol. 1975 Aug;80(2):227-34 [51591.001]
  • [Cites] Am J Physiol. 1981 Jul;241(1):F85-93 [7246778.001]
  • [Cites] Pediatrics. 1984 Jun;73(6):806-10 [6728582.001]
  • [Cites] Kidney Int. 1986 Feb;29(2):511-9 [3702209.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):637-43 [3521509.001]
  • [Cites] Ann Intern Med. 1987 May;106(5):719-27 [3551714.001]
  • [Cites] Kidney Int. 1987 Jun;31(6):1383-90 [3302507.001]
  • [Cites] Transplantation. 1988 Jan;45(1):59-65 [3276064.001]
  • [Cites] J Urol. 1988 Oct;140(4):810-1 [3418806.001]
  • [Cites] Int Urol Nephrol. 1989;21(5):547-53 [2613485.001]
  • [Cites] Kidney Int Suppl. 1989 Nov;27:S86-90 [2636678.001]
  • [Cites] Lancet. 1992 Oct 3;340(8823):807-10 [1357243.001]
  • [Cites] Am J Kidney Dis. 1993 Jun;21(6):603-11 [8503413.001]
  • [Cites] Kidney Int. 1993 May;43(5):1110-5 [8510390.001]
  • [CommentIn] N Engl J Med. 2010 Aug 19;363(8):797-8 [20818884.001]
  • [CommentIn] N Engl J Med. 2009 Jan 29;360(5):522-3 [19179321.001]
  • [CommentIn] N Engl J Med. 2009 May 28;360(22):2371-2; author reply 2372 [19484820.001]
  • [CommentIn] N Engl J Med. 2009 May 28;360(22):2371; author reply 2372 [19484821.001]
  • [CommentIn] N Engl J Med. 2009 May 28;360(22):2370-1; author reply 2372 [19484819.001]
  • [CommentIn] N Engl J Med. 2009 May 28;360(22):2370; author reply 2372 [19474439.001]
  • (PMID = 19179315.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000400; United States / NIDDK NIH HHS / DK / P01 DK013083; United States / NCRR NIH HHS / RR / M01-RR00400; United States / NIDDK NIH HHS / DK / P01DK13083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  • [Other-IDs] NLM/ NIHMS434270; NLM/ PMC3559132
  •  go-up   go-down


71. Hou CP, Chiang YJ, Chu SH, Ng KF, Wang HH: Mixed epithelial and stromal tumor of the kidney--a case report. Chang Gung Med J; 2010 Nov-Dec;33(6):693-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney--a case report.
  • She visited our hospital and a renal echo showed a heterogenous mass on the left kidney.
  • Abdominal computed tomography showed a multicystic tumor, about 7 cm, on the left renal pelvis and the proximal ureter.
  • The tumor was enhanced after contrast injection.
  • Ureteroscopy showed an intraluminal polypoid tumor.
  • Cystic renal cell carcinoma or urothelial carcinoma was suspected preoperatively.
  • The pathology report demonstrated that the tumor was composed of an admixture of stroma and flattened to cuboidal urothelium.
  • The tumor stromal cells expressed both estrogen and progesterone receptors, and no malignant cells were found.
  • There has been no recurrence or deterioration of the patient's renal function since surgery.
  • We suggest keeping in mind the diagnosis of mixed epithelial and stromal tumor of the kidney when encountering perimenopausal women with renal cystic tumors.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199615.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


72. Vassalotti JA, Stevens LA, Levey AS: Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis; 2007 Aug;50(2):169-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testing for chronic kidney disease: a position statement from the National Kidney Foundation.
  • Chronic kidney disease (CKD) is common in the United States.
  • Major outcomes of CKD include progression to kidney failure, development of complications of impaired kidney function, and increased risk for cardiovascular disease.
  • CKD is usually silent until its late stages, thus many patients with CKD are detected only shortly before the onset of symptomatic kidney failure, when there are few opportunities to prevent adverse outcomes.
  • [MeSH-major] Foundations / standards. Kidney Diseases / blood. Kidney Diseases / urine. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Kidney Dis. 2008 Jan;51(1):161-2; author reply 162-3 [18155547.001]
  • [CommentIn] Am J Kidney Dis. 2008 Jan;51(1):162; author reply 162-3 [18155548.001]
  • (PMID = 17660017.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


73. Tombul ST, Aki FT, Gunay M, Inci K, Hazirolan T, Karcaaltincaba M, Erkan I, Bakkaloglu A, Yasavul U, Bakkaloglu M: Preoperative evaluation of hilar vessel anatomy with 3-D computerized tomography in living kidney donors. Transplant Proc; 2008 Jan-Feb;40(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of hilar vessel anatomy with 3-D computerized tomography in living kidney donors.
  • OBJECTIVES: Digital subtract angiography is the gold standard for anatomic assessment of renal vasculature for living renal donors.
  • However, multidetector-row computerized tomography (MDCT) is less invasive than digital subtract angiography and provides information of kidney stones and other intra-abdominal organs.
  • In this study, preoperative MDCT angiography results were compared with the peroperative findings to evaluate the accuracy of MDCT for the evaluation of renal anatomy.
  • METHODS: From December 2002 to May 2007, all 60 consecutive living kidney donors were evaluated with MDCT angiography preoperatively.
  • We reported the number and origin of renal arteries, presence of early branching arteries, and any intrinsic renal artery disease.
  • Renal venous anatomy was evaluated for the presence of accessory, retroaortic, and circumaortic veins using venous phase axial images.
  • RESULTS: A total of 67 renal arteries were seen peroperatively in 60 renal units.
  • CONCLUSION: MDCT angiography offers a less invasive, rapid, and accurate preoperative investigation modality for vascular anatomy in living kidney donors.
  • [MeSH-major] Kidney. Living Donors. Renal Artery / anatomy & histology. Renal Circulation. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261544.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Vora N, Perrone R, Bianchi DW: Reproductive issues for adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis; 2008 Feb;51(2):307-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive issues for adults with autosomal dominant polycystic kidney disease.
  • Autosomal dominant polycystic kidney disease (ADPKD) is a common disorder.
  • Affected women with ADPKD and normal renal function have a high rate of successful uncomplicated pregnancies.
  • Pregnant women with ADPKD with compromised kidney function should be monitored carefully for the development of hypertension and preeclampsia.
  • The diagnosis of ADPKD should always be considered when prenatal sonographic findings of hyperechogenic enlarged kidneys are found.
  • In this setting, a family history and renal sonogram of both parents is indicated.
  • Sequencing of the PKD1 and PKD2 genes is available and can be used for both prenatal and preimplantation genetic diagnosis.
  • [MeSH-major] Infertility, Male / physiopathology. Polycystic Kidney, Autosomal Dominant / physiopathology. Pregnancy Complications / physiopathology. Reproduction
  • [MeSH-minor] Adult. Age of Onset. Counseling. Cysts / genetics. Female. Fetal Growth Retardation / prevention & control. Genital Diseases, Male / genetics. Humans. Hypertension, Pregnancy-Induced / prevention & control. Kidney / ultrasonography. Male. Oligohydramnios / prevention & control. Placental Circulation. Pre-Eclampsia / prevention & control. Pregnancy. Preimplantation Diagnosis. Seminal Vesicles / pathology. Sequence Analysis, DNA. Spermatozoa / abnormalities. TRPP Cation Channels. Ultrasonography, Prenatal


75. Russo P: Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther; 2006 Dec;6(12):1745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial nephrectomy achieves local tumor control and prevents chronic kidney disease.
  • Over the last 10 years, a rapidly changing clinical landscape has created an optimal environment to expand the use of partial nephrectomy for the treatment of renal cortical tumors.
  • The main factors responsible for the increasing use of partial nephrectomy relate to the appreciation of the diversity of renal cortical tumor histology, the tumor stage and size migration associated with their incidental detection, and the oncological efficacy of partial nephrectomy for tumors of 7 cm or smaller.
  • Evidence has now emerged that radical nephrectomy performed during the treatment of a small renal mass may further reduce an already impaired baseline renal function and place the patient in the realm of chronic kidney disease.
  • Important new information concerning chronic kidney disease, a condition far more prevalent in the aging US population than previously appreciated, and its associated cardiovascular morbidity and mortality, now places maximal renal functional preservation on a par with local tumor control as surgical plans are formulated for the resection of a small renal cortical tumor.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cardiovascular Diseases / etiology. Cardiovascular Diseases / mortality. Chronic Disease. Humans. Kidney Cortex / surgery. Kidney Diseases / etiology. Kidney Diseases / prevention & control. Kidney Function Tests. Kidney Transplantation. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181488.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


76. Bölling T, Janke K, Wolters HH, Glashörster M, Ernst I, Willich N, Brockmann J, Könemann S: Kidney-autotransplantation before radiotherapy: a case report. Anticancer Res; 2009 Aug;29(8):3397-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney-autotransplantation before radiotherapy: a case report.
  • BACKGROUND: A 28-year-old man suffering from a Ewing tumour arising from the 9th-11th ribs with infiltration of neuroforamina without distant metastases was planned to receive radiotherapy following primary intralesional surgery and induction chemotherapy.
  • Due to pleural infiltration and effusion, a hemithorax irradiation with a sequential boost to the primary tumour site had to be administered.
  • Different treatment planning variants failed to provide sufficient radiotherapy planning in view of target volume coverage and avoidance of organs at risk, especially due to high calculated radiation doses potentially compromising the left kidney.
  • MATERIALS AND METHODS: To prevent left kidney organ exposure, an autotransplantation of the left kidney into the right fossa iliaca was performed.
  • An infiltration of the kidney was initially excluded.
  • RESULTS: Postoperatively, a renal scintigraphy showed a normal function of both kidneys allowing sufficient radiotherapy treatment planning.
  • [MeSH-major] Bone Neoplasms / surgery. Kidney Transplantation. Sarcoma, Ewing / surgery
  • [MeSH-minor] Adult. Humans. Kidney / radiation effects. Kidney / surgery. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Intensity-Modulated. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661363.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


77. Hao CM, Breyer MD: Roles of lipid mediators in kidney injury. Semin Nephrol; 2007 May;27(3):338-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of lipid mediators in kidney injury.
  • In addition to their role in regulating normal kidney function, these lipids also play important roles in the pathogenesis of kidney diseases.
  • P450 arachidonic acid mono-oxygenase-derived 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids are involved in several forms of kidney injury, including renal injury in metabolic syndrome.
  • Ceramide also has been shown to be an important signaling molecule that is involved in the pathogenesis of acute kidney injury caused by ischemia/reperfusion and toxic insults.
  • Those pathways should provide fruitful targets for intervention in the pharmacologic treatment of renal disease.
  • [MeSH-major] Kidney Diseases / metabolism. Leukotrienes / physiology. Lipoxygenase / physiology. Prostaglandin-Endoperoxide Synthases / metabolism. Prostaglandins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533010.001).
  • [ISSN] 0270-9295
  • [Journal-full-title] Seminars in nephrology
  • [ISO-abbreviation] Semin. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Cyclooxygenase Inhibitors; 0 / Leukotrienes; 0 / Prostaglandins; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.13.11.12 / Lipoxygenase; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Number-of-references] 178
  •  go-up   go-down


78. Filimonovic D, Gojnic M, Arsenijevic Lj, Popovic N, Dugalic V: Increased AFP as an indicator of ovarian carcinoma and fetal kidney carcinoma--case report. Eur J Gynaecol Oncol; 2007;28(1):57-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased AFP as an indicator of ovarian carcinoma and fetal kidney carcinoma--case report.
  • Having in mind a mild decrease in ovarian artery resistance index (RI) and suspected findings of fetal kidney, this situation was delicate due to its double pathology which was later confirmed.
  • Wilms' tumor is the most common urogenital tumor in childhood, and it is detectable in the prenatal period by ultrasound examination.
  • In utero kidney biopsy confirms diagnosis and facilitates decisions concerning the course of pregnancy.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Wilms Tumor / diagnosis. alpha-Fetoproteins / metabolism


79. Raiteri M, Ferraresso M, Pozzoli E, Beretta C, Pasciucco A, Carini M, Berardinelli L: Value of intraoperative resistive index in kidney transplant. Transplant Proc; 2005 Jul-Aug;37(6):2472-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of intraoperative resistive index in kidney transplant.
  • The value of the resistive index (RI) obtained by echo color doppler evaluation of the transplanted kidney is still not well established.
  • Many authors consider the RI to be nonspecific sign of rejection, acute tubular necrosis, or urinary tract obstruction, but its specificity remains low.
  • In this paper, we report our experience with RI determinations in 34 consecutive kidney transplants at different times namely: perioperatively, at 24 hours, at 3 days, at 6 and at 9 days posttransplant.
  • In all patients intraoperative RI was normal.
  • RI increased significantly after transplantation in 10 patients who eventually developed a complication: delayed function, acute rejection, and spontaneous kidney ruptures.
  • This increment from the baseline value was already significant at 24 hours after the kidney transplant, indicating a possible posttransplant complication (0.62 +/- 0.07 vs 0.76 +/- 0.04; P = .0004).
  • We conclude that the value of RI in the early posttransplant phase should be considered an important aid for the early diagnosis of posttransplant complications.
  • [MeSH-major] Kidney Transplantation / physiology. Vascular Resistance
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Monitoring, Intraoperative. Postoperative Period. Preoperative Care. Renal Circulation / physiology. Tissue Donors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182713.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Phisitkul S, Hacker C, Simoni J, Tran RM, Wesson DE: Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors. Kidney Int; 2008 Jan;73(2):192-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors.
  • Dietary casein promotes a progressive decline in the glomerular filtration rate (GFR) of remnant kidneys associated with metabolic acidosis and an endothelin-mediated increase in renal acidification.
  • We tested whether diets that affect the acid-base status contributes to the decline of GFR through endothelin receptors in rats with a remnant kidney.
  • Rats on a casein diet had metabolic acidosis at baseline and developed a progressive decline in GFR after renal mass reduction.
  • Dietary soy protein did not induce baseline metabolic acidosis and rats with remnant kidney on a soy diet had no decrease in their GFR.
  • By contrast, rats with a remnant kidney on soy protein given dietary acid developed metabolic acidosis and a decreased GFR.
  • Our study suggests that the casein-induced decline in GFR of the remnant kidney is mediated by metabolic acidosis through endothelin A receptors.


81. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Southern DA, McLaughlin K, Mortis G, Culleton BF: Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int; 2006 Jun;69(12):2155-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of kidney dysfunction in the community-dwelling elderly.
  • Despite the high prevalence of chronic kidney disease among the elderly, few studies have described their loss of kidney function.
  • We sought to determine the progression of kidney dysfunction among a community-based cohort of elderly subjects.
  • In conclusion, we found that the majority of elderly subjects have no or minimal progression of kidney disease over 2 years.
  • Strategies aimed at slowing progression of kidney disease should consider underlying risk factors for progression and the negligible loss of kidney function that occurs in the majority of older adults.
  • [MeSH-major] Aging / physiology. Glomerular Filtration Rate / physiology. Kidney / physiopathology. Kidney Failure, Chronic / physiopathology


82. McClellan WM, Casey MT, Hughley J, Freund E: Population-based interventions to reduce socioeconomic disparities in chronic kidney disease. Semin Nephrol; 2010 Jan;30(1):33-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based interventions to reduce socioeconomic disparities in chronic kidney disease.
  • Disparities in the occurrence and outcomes of chronic kidney disease (CKD) are associated with individual and community socioeconomic (SES) risk factors.
  • Changes in the US health system have eliminated barriers to access for end-stage renal disease care for most US citizens and reduced disparities in outcomes of care after the onset of renal replacement therapy.
  • In particular, we describe a 10-state pilot project initiated by the Centers for Medicare and Medicaid Services in August of 2008 to reduce disparities and improve the detection and treatment of early diabetic kidney disease.
  • [MeSH-major] Healthcare Disparities. Kidney Diseases / therapy

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20116646.001).
  • [ISSN] 1558-4488
  • [Journal-full-title] Seminars in nephrology
  • [ISO-abbreviation] Semin. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Laissy JP, Idée JM, Fernandez P, Floquet M, Vrtovsnik F, Schouman-Claeys E: Magnetic resonance imaging in acute and chronic kidney diseases: present status. Nephron Clin Pract; 2006;103(2):c50-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in acute and chronic kidney diseases: present status.
  • Magnetic resonance imaging (MRI) of normal and diseased kidneys shows great promise because of the combined value of anatomical and functional information provided, as well as of specific contrast patterns that can be observed non-invasively.
  • Multicontrast MRI is able to show infiltrative kidney disorders.
  • Diffusion-weighted imaging can assess alterations in renal function and can suggest obstruction or inflammation when present.
  • Furthermore, contrast agents such as ultrasmall particles of iron oxide, specific of inflammation, should be used in the near future to detect active from quiescent involvement, both in native kidneys and renal allografts.
  • Ongoing studies will obviously demonstrate the value of the combination of these various MRI sequences in the diagnosis of acute renal failure and chronic kidney disease.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Kidney Failure, Chronic / diagnosis. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16543756.001).
  • [ISSN] 1660-2110
  • [Journal-full-title] Nephron. Clinical practice
  • [ISO-abbreviation] Nephron Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 34
  •  go-up   go-down


84. Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS: Adiponectin receptor expression in human malignant tissues. Horm Cancer; 2010 Jun;1(3):136-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48).
  • To compare expression in malignant versus nonmalignant tissues, we also studied AdipoR1 and AdipoR2 expression in pairs of renal cell carcinoma and adjacent healthy kidney tissue specimens by immunohistochemistry.
  • We also studied mRNA expression in 45 specimens of renal cell carcinoma by real-time polymerase chain reaction.
  • Finally, we utilized Western blotting to confirm the presence of adiponectin receptors and subsequently studied cell signaling pathways of adiponectin in the renal cancer cell line 786-O.
  • Of the specimens of renal cell carcinoma, which is strongly associated with obesity, 93.8% expressed AdipoR1 compared to 44.9% of the specimens of cervical cell carcinoma, which is not associated with obesity (p < 0.001).
  • There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens.
  • Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors.
  • Finally, Western blotting confirmed the presence of AdipoR1 in the renal cancer cell line 786-O, and adiponectin activates in vitro several signaling pathways in this cell line.
  • [MeSH-major] Neoplasms / metabolism. Receptors, Adiponectin / biosynthesis
  • [MeSH-minor] Adult. Aged. Blotting, Western. Carcinoma, Renal Cell / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism. Male. Middle Aged. Obesity / complications. Obesity / metabolism. RNA, Messenger / analysis. Real-Time Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] Oncology. 2007;73(3-4):261-9 [18424891.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):339-44 [19148467.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):597-605 [17763959.001]
  • [Cites] Cancer Lett. 2010 Feb 28;288(2):177-82 [19646806.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Endocrinology. 2010 Jan;151(1):115-22 [19887569.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Jpn J Clin Oncol. 2008 Feb;38(2):106-11 [18245516.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):79-87 [15936715.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):405-10 [18163210.001]
  • [Cites] Maturitas. 2009 Jul 20;63(3):253-6 [19524379.001]
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):555-61 [8406981.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103(2):137-42 [12149104.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50 [18313838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Obstet Gynecol Surv. 2005 Oct;60(10):683-92 [16186785.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Obesity (Silver Spring). 2006 Jan;14(1):28-35 [16493120.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8 [17192291.001]
  • [Cites] Trends Pharmacol Sci. 2005 Feb;26(2):69-76 [15681023.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Oncol Rep. 2008 Oct;20(4):971-7 [18813842.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18341-7 [15734737.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):374-80 [18818986.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):705-9 [19638541.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):140-6 [17036323.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):866-73 [18343565.001]
  • [Cites] Int J Obes (Lond). 2007 Dec;31(12):1843-8 [17607322.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1573-8 [17205522.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3321-7 [19661351.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Gut. 2008 Nov;57(11):1531-8 [18676419.001]
  • [Cites] Lung Cancer. 2008 Sep;61(3):391-7 [18342391.001]
  • [Cites] Cancer Causes Control. 2009 Jul;20(5):625-33 [19051043.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1214-21 [18483344.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1120-7 [17459059.001]
  • (PMID = 21761356.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Adiponectin
  •  go-up   go-down


85. O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB: Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med; 2009 May 19;150(10):717-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?
  • Angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists are recommended for patients with chronic kidney disease because these drugs can slow disease progression.
  • Older adults account for a large and growing number of patients with chronic kidney disease.
  • The authors evaluated the relevance to adults older than 70 years of the evidence base for major U.S. practice guidelines for the use of these agents in chronic kidney disease.
  • The authors first examined the representation of older adults in randomized trials that underpin these guidelines, then compared the characteristics of participants in these trials with those of a representative sample of older adults with chronic kidney disease in the general population.
  • The authors found that current guidelines for the use of angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease are based on evidence with limited relevance to most persons older than 70 years with this condition.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Intern Med. 2009 May 19;150(10):731-3 [19451583.001]
  • (PMID = 19451579.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K23 AG028980; United States / NIA NIH HHS / AG / K 1K23AG28980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


86. Surányi A, Nyári T, Keresztúri A, Látó K, Pál A: [Biparietal diameter/kidney length ratio in cases with chronic hypoxic state]. Orv Hetil; 2005 Oct 16;146(42):2163-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biparietal diameter/kidney length ratio in cases with chronic hypoxic state].
  • AIMS: The object of this study was to investigate the fetal biparietal diameter/kidney length ratio in normal and hyperechogenic kidneys during the third trimester of gestation.
  • Depending on the renal manifestation of intrauterine chronic hypoxia, cases were divided into two study groups.
  • Group I was composed of 21 fetuses with pregnancy-associated hypertension and/or proteinuria and hyperechogenic renal medullae.
  • Group II consisted of 162 fetuses with pregnancy-associated hypertension and/or proteinuria and normal echoic kidney.
  • RESULTS: Fetal renal hyperechogenicity correlated with the pathological growth of fetal kidney.
  • The fetal biparietal diameter/kidney length ratio was significantly lower in cases of hyperechogenicity.
  • CONCLUSIONS: The fetal renal hyperechogenicity is a relevant indicator of diminution of fetal renal perfusion.
  • This can lead to abnormal development of the affected kidney and can result in a pathological reduction of biparietal diameter/kidney length ratio, which may also be an in utero indicator of subsequent intrauterine and neonatal complications.
  • Detailed ultrasound examinations of renal parenchyma and kidney length seem to be a useful method in the prenatal diagnosis of decreased renal perfusion and of intrauterine hypoxia and serve to detect pathological conditions in utero.
  • [MeSH-major] Fetal Hypoxia / pathology. Kidney / pathology. Pregnancy Complications / pathology. Pregnancy Trimester, Third. Ultrasonography, Prenatal

  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315998.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


87. Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Chen YD, de Boer IH, Haritunians T, Lumley T, Sarnak M, Siscovick D, Benjamin EJ, Levy D, Upadhyay A, Aulchenko YS, Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, Chasman DI, Paré G, Ridker PM, Kao WH, Witteman JC, Coresh J, Shlipak MG, Fox CS: Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet; 2009 Jun;41(6):712-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple loci associated with indices of renal function and chronic kidney disease.
  • Chronic kidney disease (CKD) has a heritable component and is an important global public health problem because of its high prevalence and morbidity.
  • UMOD encodes the most common protein in human urine, Tamm-Horsfall protein, and rare mutations in UMOD cause mendelian forms of kidney disease.
  • Our findings provide new insights into CKD pathogenesis and underscore the importance of common genetic variants influencing renal function and disease.

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 2004 May;43(5):796-800 [15112169.001]
  • [Cites] J Am Soc Nephrol. 2004 Sep;15(9):2457-61 [15339995.001]
  • [Cites] Peptides. 2004 Oct;25(10):1663-9 [15476933.001]
  • [Cites] J Med Genet. 1990 Dec;27(12):729-37 [2074558.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Kidney Int. 2005 Jan;67(1):61-9 [15610228.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Mar;288(3):F559-67 [15522986.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2000 May;9(3):273-7 [10847329.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 [11904577.001]
  • [Cites] Am J Kidney Dis. 2002 May;39(5):920-9 [11979335.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):882-92 [12471200.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4):658-76 [14520616.001]
  • [Cites] Circulation. 2003 Oct 28;108(17):2154-69 [14581387.001]
  • [Cites] Hum Mol Genet. 2003 Dec 15;12(24):3369-84 [14570709.001]
  • [Cites] J Am Soc Nephrol. 2004 May;15(5):1307-15 [15100371.001]
  • [Cites] JAMA. 2005 Jun 15;293(23):2892-9 [15956634.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2473-83 [16760447.001]
  • [Cites] Kidney Int. 2006 Sep;70(6):1155-69 [16883323.001]
  • [Cites] Kidney Int. 2007 Aug;72(3):247-59 [17568785.001]
  • [Cites] PLoS Genet. 2007 Jul;3(7):e114 [17676998.001]
  • [Cites] BMC Med Genet. 2007;8 Suppl 1:S10 [17903292.001]
  • [Cites] JAMA. 2007 Nov 7;298(17):2038-47 [17986697.001]
  • [Cites] Am J Kidney Dis. 2008 Mar;51(3):395-406 [18295055.001]
  • [Cites] Development. 2008 Apr;135(8):1493-502 [18339671.001]
  • [Cites] Genet Epidemiol. 2008 May;32(4):381-5 [18348202.001]
  • [Cites] BMC Public Health. 2008;8:117 [18405348.001]
  • [Cites] Am J Kidney Dis. 2009 Feb;53(2):327-31 [18950917.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1368-78 [19246645.001]
  • [Cites] Circ Cardiovasc Genet. 2009 Feb;2(1):73-80 [20031568.001]
  • (PMID = 19430482.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / N01HC55020; United States / NCRR NIH HHS / RR / UL1RR025005; United States / NHLBI NIH HHS / HL / N02-HL-6-4278; United States / NHLBI NIH HHS / HC / N01-HC-25195; United States / NHLBI NIH HHS / HC / N01 HC055022; United States / NHLBI NIH HHS / HC / N01 HC085086; United States / NIDDK NIH HHS / DK / K01 DK067207; United States / NIA NIH HHS / AG / R01 AG027002-01; United States / NIA NIH HHS / AG / N01AG12100; United States / NCRR NIH HHS / RR / KL2 RR025015-03; United States / NHLBI NIH HHS / HL / N01HC55018; United States / NHLBI NIH HHS / HC / N01-HC-85085; United States / NHLBI NIH HHS / HL / R01HL59367; United States / NCRR NIH HHS / RR / UL1 RR025005; United States / NHGRI NIH HHS / HG / U01 HG004402-01; United States / NIA NIH HHS / AG / N01 AG012100; United States / NIDDK NIH HHS / DK / DK067207-01A1; United States / NHLBI NIH HHS / HL / U01 HL080295; United States / NHLBI NIH HHS / HL / HL 043851; United States / NIDDK NIH HHS / DK / K01 DK067207-01A1; United States / NHLBI NIH HHS / HC / N01 HC075150; United States / NHLBI NIH HHS / HC / N01-HC-55022; United States / NHLBI NIH HHS / HC / N01-HC-85081; United States / NHLBI NIH HHS / HL / R01 HL043851; United States / NHLBI NIH HHS / HL / R01 HL059367; United States / NHLBI NIH HHS / HC / N01 HC015103; United States / NCRR NIH HHS / RR / M01 RR000069; United States / NHLBI NIH HHS / HC / N01-HC-55016; United States / NHLBI NIH HHS / HC / N01 HC055018; United States / NHLBI NIH HHS / HC / N01 HC025195; United States / NHLBI NIH HHS / HL / R01 HL086694; United States / NHLBI NIH HHS / HL / N02 HL64278; United States / NHLBI NIH HHS / HL / HL087652-01; United States / NHLBI NIH HHS / HL / R01 HL087652; None / None / / KL2 RR025015-03; United States / NHLBI NIH HHS / HL / R01 HL059367-02; United States / PHS HHS / / HHSN268200625226C; United States / NHGRI NIH HHS / HG / U01 HG004402; United States / NHLBI NIH HHS / HL / N01HC55022; United States / NHLBI NIH HHS / HL / N01HC55222; United States / NHLBI NIH HHS / HC / N01-HC-55021; United States / NHLBI NIH HHS / HC / N01-HC-85086; United States / NHLBI NIH HHS / HL / N01HC55015; United States / NHLBI NIH HHS / HL / N01HC85086; United States / NHGRI NIH HHS / HG / U01HG004402; United States / NCI NIH HHS / CA / CA 047988; United States / NIDDK NIH HHS / DK / K01DK067207; United States / NHLBI NIH HHS / HC / N01-HC-85082; United States / NHLBI NIH HHS / HC / N01 HC055019; United States / NIDDK NIH HHS / DK / P30 DK063491; United States / Intramural NIH HHS / / ; United States / NHLBI NIH HHS / HC / N01-HC-35129; United States / NIDDK NIH HHS / DK / P30 DK063491-019004; United States / NHLBI NIH HHS / HC / N01-HC-55019; United States / NIDDK NIH HHS / DK / DK063491-019004; United States / NIDDK NIH HHS / DK / DK063491-05; United States / NHLBI NIH HHS / HL / R01HL087641; United States / NHLBI NIH HHS / HC / N01-HC-55015; United States / NHLBI NIH HHS / HC / N01 HC055222; United States / NHLBI NIH HHS / HL / R01 HL086694-01A1; United States / NHLBI NIH HHS / HC / N01-HC-55222; United States / NCRR NIH HHS / RR / M01RR00069; United States / NHLBI NIH HHS / HC / N01-HC-85083; United States / NHLBI NIH HHS / HC / N01-HC-75150; United States / NHLBI NIH HHS / HC / N01-HC-55020; United States / NHLBI NIH HHS / HC / N01-HC-85080; United States / NHLBI NIH HHS / HC / N01 HC-15103; United States / NHLBI NIH HHS / HL / N01HC55016; United States / NIDDK NIH HHS / DK / R01 DK076770; United States / NHLBI NIH HHS / HL / R01 HL043851-09; United States / NIDDK NIH HHS / DK / P30 DK063491-05; United States / NHLBI NIH HHS / HC / N01 HC055015; United States / NIA NIH HHS / AG / R01 AG027002; United States / NHLBI NIH HHS / HC / N01 HC055021; None / None / / U01 HL080295-01; United States / NCI NIH HHS / CA / R01 CA047988; United States / NCRR NIH HHS / RR / UL1 RR025005-01; United States / NHLBI NIH HHS / HL / N01HC55019; United States / NHLBI NIH HHS / HL / N01HC75150; United States / NIA NIH HHS / AG / N01-AG-12100; United States / NHLBI NIH HHS / HL / HL059367-02; United States / NCRR NIH HHS / RR / KL2 RR025015; United States / NHLBI NIH HHS / HL / N01HC25195; United States / NHLBI NIH HHS / HL / R01 HL087641-01; United States / NIDDK NIH HHS / DK / DK063491; United States / NHLBI NIH HHS / HC / N01-HC-45133; United States / NHLBI NIH HHS / HC / N01-HC-85079; United States / NHLBI NIH HHS / HC / N01 HC055020; United States / NCATS NIH HHS / TR / UL1 TR000423; United States / NHLBI NIH HHS / HL / R01 HL087652-01; United States / NHLBI NIH HHS / HL / N01HC85079; United States / NHLBI NIH HHS / HC / N01 HC085079; United States / NIA NIH HHS / AG / AG012100; United States / NHLBI NIH HHS / HC / N01-HC-55018; United States / NHLBI NIH HHS / HL / N01HC55021; United States / NHLBI NIH HHS / HL / R01 HL087641; United States / NHLBI NIH HHS / HL / HL086694-01A1; United States / NHLBI NIH HHS / HC / N01 HC045133; United States / NHLBI NIH HHS / HC / N01 HC035129; United States / NHLBI NIH HHS / HC / N01 HC055016; United States / NHLBI NIH HHS / HC / N01-HC-85084; United States / NHLBI NIH HHS / HL / R01HL086694; United States / NHLBI NIH HHS / HL / U01 HL080295-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucoproteins; 0 / UMOD protein, human; 0 / Uromodulin
  • [Other-IDs] NLM/ NIHMS267520; NLM/ PMC3039280
  •  go-up   go-down


88. Manuel O, Pascual M, Trendelenburg M, Meylan PR: Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation; 2007 Feb 15;83(3):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation.
  • We measured plasma MBL levels in 16 kidney transplant recipients with high-risk CMV serostatus (donor-positive/recipient-negative).
  • MBL deficiency may be a significant risk factor for the development of CMV infection in kidney transplant recipients, suggesting a role for innate immunity in the control of CMV infection after organ transplantation.
  • [MeSH-major] Cytomegalovirus Infections / etiology. Kidney Transplantation. Mannose-Binding Lectin / deficiency


89. Hanish SI, Samaniego M, Mezrich JD, Foley DP, Leverson GE, Lorentzen DF, Sollinger HW, Pirsch JD, D'Alessandro AM, Fernandez LA: Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation; 2010 Jul 15;90(1):52-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report.
  • BACKGROUND: With adoption of Model for End-Stage Liver Disease, the number of simultaneous liver-kidney transplants (SLK) has greatly increased.
  • A recent registry study questioned the equity of allocating kidney transplants (KTx) simultaneously with liver transplantation due to poor outcomes (Locke et al., Transplantation 2008; 85: 935).
  • METHODS: To investigate outcome of KTx in SLK, all SLK (n=36) performed at our center from January 2000 to December 2007 were reviewed and KTx outcomes compared with those of kidney transplant alone (KTA) performed during that period (n=1283).

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Transplant. 2009 Mar;9(3):578-85 [19260837.001]
  • [Cites] Am J Transplant. 2003 Mar;3(3):348-56 [12614293.001]
  • [Cites] Transplant Proc. 2008 Dec;40(10):3424-7 [19100404.001]
  • [Cites] Transplantation. 2008 Dec 15;86(11):1548-53 [19077888.001]
  • [Cites] Transplant Proc. 2008 Jul-Aug;40(6):1867-8 [18675073.001]
  • [Cites] Transplantation. 2008 Apr 15;85(7):935-42 [18408571.001]
  • [Cites] Liver Transpl. 2007 Jun;13(6):838-43 [17539003.001]
  • [Cites] Transplantation. 2006 Nov 27;82(10):1298-303 [17130778.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2183-90 [16827789.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):735-41; discussion 741-2 [16924080.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1125-6 [16757284.001]
  • [Cites] Transplant Proc. 2006 May;38(4):1086-8 [16757272.001]
  • [Cites] Liver Transpl. 2005 Nov;(11 Suppl 2):S35-44 [16237696.001]
  • [Cites] Liver Transpl. 2005 Sep;11(9):1022-5 [16123956.001]
  • [Cites] Liver Transpl Surg. 1999 Jul;5(4):261-8 [10388498.001]
  • [Cites] Liver Transpl. 2003 Oct;9(10):1067-78 [14526402.001]
  • [Cites] Am J Transplant. 2004 Oct;4(10):1562-6 [15367210.001]
  • [Cites] Hepatology. 2002 May;35(5):1179-85 [11981768.001]
  • [Cites] Transpl Int. 2009 Feb;22(2):242-6 [18954373.001]
  • (PMID = 20626084.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] ENG
  • [Grant] None / None / / UL1 RR025011-01; United States / NCRR NIH HHS / RR / UL1 RR025011-03; United States / NCRR NIH HHS / RR / UL1 RR025011-01; None / None / / UL1 RR025011-05; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCRR NIH HHS / RR / UL1 RR025011-02; United States / NCRR NIH HHS / RR / UL1 RR025011-05; None / None / / UL1 RR025011-03; United States / NCRR NIH HHS / RR / UL1 RR025011-04; None / None / / UL1 RR025011-04; None / None / / UL1 RR025011-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS279256; NLM/ PMC3085017
  •  go-up   go-down


90. Mironov V, Drake C, Wen X: Research project: Charleston Bioengineered Kidney Project. Biotechnol J; 2006 Sep;1(9):903-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Research project: Charleston Bioengineered Kidney Project.
  • The goal of Charleston Bioengineered Kidney Project is to engineer a functional living human kidney suitable for surgical implantation using principles of directed tissue self-assembly and tissue fusion.
  • The conceptual framework, engineering principles, design, potential cell source as well as the first preliminary data demonstrating the feasibility of the proposed Charleston Bioengineered Kidney Project are outlined.
  • [MeSH-major] Bioartificial Organs. Biotechnology / methods. Kidney / anatomy & histology. Kidney / physiology. Tissue Engineering / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986103.001).
  • [ISSN] 1860-7314
  • [Journal-full-title] Biotechnology journal
  • [ISO-abbreviation] Biotechnol J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biocompatible Materials
  •  go-up   go-down


91. Bivol LM, Vågnes OB, Iversen BM: The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol; 2005 Aug;289(2):F393-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The renal vascular response to ANG II injection is reduced in the nonclipped kidney of two-kidney, one-clip hypertension.
  • The ANG II receptor 1 (AT(1)R) level in the nonclipped kidney of two-kidney, one-clip hypertension (2K1C) has shown to be unchanged despite a high circulating angiotensin (ANG) II level.
  • To examine the vasoreactive response to ANG II in this kidney, injections of ANG II into renal artery were performed 6 wk after clipping of the kidney and compared with normotensive controls.
  • The renal blood flow (RBF) response to 2.5 ng ANG II was measured by a Transonic transit-time flowmeter, before and after indomethacin and candesartan treatment, and analyzed by a computer program.
  • The mRNA for AT(1A) and AT(1B) as well as Western blotting for AT(1)R in renal resistance vessels were determined, and plasma renin activity (PRA) was measured.
  • Injection of ANG II reduced RBF with 10 +/- 2% in the nonclipped kidney and 24 +/- 3% in controls (P < 0.001).
  • The doses of candesartan needed to completely inhibit RBF response to ANG II were 30 microg/kg in the nonclipped kidney and 100 microg/kg in controls (P < 0.001).
  • Western blotting and mRNA for AT(1A) and AT(1B) in the nonclipped kidney were similar to the controls.
  • The results indicate that despite no difference in total AT(1)R levels, functional AT(1)R is downregulated in the nonclipped kidney of 2K1C rats.
  • [MeSH-major] Angiotensin II / pharmacology. Hypertension, Renovascular / physiopathology. Renal Circulation / drug effects

  • Hazardous Substances Data Bank. CANDESARTAN .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15784843.001).
  • [ISSN] 1931-857X
  • [Journal-full-title] American journal of physiology. Renal physiology
  • [ISO-abbreviation] Am. J. Physiol. Renal Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzimidazoles; 0 / Cyclooxygenase Inhibitors; 0 / Proteins; 0 / RNA, Messenger; 0 / Receptors, Angiotensin; 0 / Tetrazoles; 0 / Vasoconstrictor Agents; 11128-99-7 / Angiotensin II; 113-79-1 / Arginine Vasopressin; 63231-63-0 / RNA; EC 3.4.23.15 / Renin; S8Q36MD2XX / candesartan; XXE1CET956 / Indomethacin
  •  go-up   go-down


92. Pietrzak-Nowacka M, Safranow K, Byra E, Nowosiad M, Marchelek-Myśliwiec M, Ciechanowski K: Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest; 2010 Dec;70(8):561-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease.
  • OBJECTIVE: The aim of the study was to estimate the pancreatic beta cell function and insulin resistance indexes in a group of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with normal kidney function and no previous diabetes mellitus diagnosis.
  • CONCLUSIONS: Presence of ADPKD in patients with normal kidney function is associated with impaired beta cell function after an oral glucose load, without a significant decrease in insulin sensitivity.
  • [MeSH-major] Glucose / metabolism. Glucose Tolerance Test / methods. Polycystic Kidney, Autosomal Dominant / metabolism


93. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens; 2008 Nov;17(6):609-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
  • These preclinical findings are thought to be of major importance as ADMA predicts cardiovascular events and mortality in the general population and in patients with chronic kidney disease.
  • Also, ADMA uniformly predicts the progression of moderate and severe chronic kidney disease.
  • Symmetrical dimethylarginine, the structural isomer of ADMA, which was mistakenly thought to be without biological relevance, indicates the degree of renal impairment.
  • SUMMARY: ADMA also beautifully explains many facets of the pathophysiology of chronic kidney disease.
  • Future preclinical and especially clinical studies are required to prove the importance of ADMA in renal and cardiovascular disease.
  • [MeSH-major] Arginine / analogs & derivatives. Kidney Diseases / therapy

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941355.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 30315-93-6 / N,N-dimethylarginine; 9002-72-6 / Growth Hormone; 94ZLA3W45F / Arginine; EC 3.5.- / Amidohydrolases; EC 3.5.3.18 / dimethylargininase
  • [Number-of-references] 69
  •  go-up   go-down


94. Sankaran D, Bankovic-Calic N, Peng CY, Ogborn MR, Aukema HM: Dietary flax oil during pregnancy and lactation retards disease progression in rat offspring with inherited kidney disease. Pediatr Res; 2006 Dec;60(6):729-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary flax oil during pregnancy and lactation retards disease progression in rat offspring with inherited kidney disease.
  • Dietary flax oil (FO) retards disease progression in growing or adult animal models of kidney disease.
  • To determine whether dietary flax oil during the perinatal period would alter renal disease progression in offspring, Han-SPRD-cy rats with inherited cystic kidney disease were given diets with either 7% FO or corn oil (CO), throughout pregnancy and lactation.
  • Rats given FO during the maternal period had 15% less renal cyst growth compared with rats given FO only in the postweaning period.
  • Dietary FO, compared with CO, in the maternal period also resulted in 12% lower cell proliferation and 15% less oxidant injury in diseased kidneys of offspring.
  • Including FO in both the maternal and postweaning period resulted in 29-34% less renal interstitial fibrosis and 22-23% lower glomerular hypertrophy.
  • The potential for dietary FO during pregnancy and lactation to positively modulate adult renal disease has significant implications for the 1 in 1000 individuals with congenital cystic kidney disease.
  • [MeSH-major] Dietary Fats, Unsaturated / pharmacology. Lactation / physiology. Linseed Oil / pharmacology. Polycystic Kidney Diseases / genetics. Polycystic Kidney Diseases / physiopathology. Pregnancy, Animal / physiology
  • [MeSH-minor] Animals. Animals, Newborn. Cell Proliferation. Disease Progression. Female. Fibrosis / pathology. Hypertrophy / pathology. Kidney / metabolism. Kidney / pathology. Male. Pregnancy. Rats. Rats, Mutant Strains

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065582.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats, Unsaturated; 8001-26-1 / Linseed Oil
  •  go-up   go-down


95. Rozanec JJ, Ameri C, Holst P, Featherston M, Vallone C, Atchabahián P, Hernández A, Nolazco A, Ares J, Mazza O: Nephron-sparing surgery: our experience in open and laparoscopic approach in 254 cases. Arch Esp Urol; 2010 Jan-Feb;63(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The majority of renal cell carcinomas are now incidentally detected as small renal masses in asymptomatic patients due to the widespread use of ultrasound and new improved noninvasive abdominal imaging modalities.
  • Nephron-sparing surgery is the treatment of choice for patients with small renal masses in presence of normal contralateral kidney or in presence of an anatomic or functional solitary kidney.
  • METHODS: The records for all patients who underwent nephron-sparing surgery for a renal mass since 1995 at British Hospital of Buenos Aires and Hospital Aleman and since 2000 at Hospital Universitario Austral were reviewed.
  • The indication was elective or relative in 236 patients with 8 patients with bilateral tumors and 18 tumors in a solitary kidney.
  • Average tumor size was 3.49 cm.
  • The pathologic findings demonstrate a carcinoma in 193 cases and benign lesions in 61 patients (24%).
  • One patient presented a positive surgical margin in the pathologic examination, but subsequent nephrectomy was negative for residual tumor.
  • One patient presented a pseudo-tumoral mass on follow-up on CT scan and MRI, but nephrectomy was negative for residual tumor.
  • One patient developed a tumor in the contralateral kidney 20 months after partial nephrectomy and another one 10 years later.
  • CONCLUSIONS: Open partial nephrectomy is considered nowadays the gold standard treatment of small renal masses, and in our experience it is a safe and effective technique of treatment of these tumors.
  • [MeSH-major] Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Esp Urol. 2010 Jan-Feb;63(1):70 [21109715.001]
  • (PMID = 20157221.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


96. Boschiero L, Fior F, Nacchia F: Bimodal distribution of major cardiovascular events in kidney allograft recipients. Transplant Proc; 2009 May;41(4):1183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bimodal distribution of major cardiovascular events in kidney allograft recipients.
  • Cardiovascular disease (CVD) is the major cause of death after renal transplantation.
  • We have retrospectively analyzed the incidence and the time of appearance of CVD among 870 consecutive cadaveric kidney transplant recipients, including 143 patients (16.5%) who experienced a fatal or nonfatal event after transplantation.
  • This trend of CVD after kidney transplantation may be explained by inadequate evaluation and management of CVD risk factors during waiting list time and, after transplantation, by the cumulative effects of traditional and nontraditional risk factors.
  • [MeSH-major] Cardiovascular Diseases / epidemiology. Kidney Transplantation

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460511.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Palmer S, McGregor DO, Strippoli GF: Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev; 2005;(2):CD005015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for preventing bone disease in kidney transplant recipients.
  • BACKGROUND: Patients with chronic kidney disease have significant abnormalities of bone remodelling and calcium homeostasis and are at increased risk of fracture.
  • The fracture risk for a kidney transplant recipient is four times that of the general population and higher than that for a patient on dialysis.
  • OBJECTIVES: To evaluate the use of interventions for the treatment of bone disease following kidney transplantation.
  • SELECTION CRITERIA: Randomised trials of treatment of bone disease following kidney transplantation were included.
  • Trials of recipients of any transplant other than a kidney transplant including trials of kidney-pancreas transplants were excluded.
  • AUTHORS' CONCLUSIONS: No benefit from any intervention known to reduce risk of fracture from bone disease could be demonstrated to reduce fracture incidence in kidney transplant recipients.
  • [MeSH-major] Fractures, Bone / prevention & control. Kidney Transplantation / adverse effects
  • [MeSH-minor] Bone Diseases / etiology. Bone Diseases / prevention & control. Calcitonin / therapeutic use. Calcium / therapeutic use. Diphosphonates / therapeutic use. Female. Humans. Kidney Diseases / complications. Male. Randomized Controlled Trials as Topic. Vitamin D / therapeutic use

  • Genetic Alliance. consumer health - Kidney Disease.
  • MedlinePlus Health Information. consumer health - Fractures.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2007;(3):CD005015 [17636784.001]
  • (PMID = 15846740.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 1406-16-2 / Vitamin D; 9007-12-9 / Calcitonin; SY7Q814VUP / Calcium
  • [Number-of-references] 64
  •  go-up   go-down


98. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N: Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol; 2008 Mar-Apr;18(2):97-115
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C virus infection in haemodialysis and kidney transplant patients.
  • The prevalence of HCV is significantly higher in haemodialysis and kidney transplant patients, as compared to the general population.
  • Likewise, HCV has a detrimental effect on both patient and graft survival after kidney transplantation.
  • However, patient survival is significantly better with kidney transplantation compared to remaining on dialysis; therefore, HCV infection alone should not be a contraindication to transplantation.
  • Interferon-alpha (standard/pegylated) is relatively contraindicated after kidney transplantation because of an increased risk of allograft rejection.
  • Therefore, antiviral treatment of transplant candidates while on dialysis remains the best option and may avoid the risk of HCV-associated liver and renal disease after transplantation.
  • Large multi-centre clinical trials are required in HCV-infected haemodialysis and kidney transplant patients in order to define optimal therapeutic strategies before and after transplantation.
  • [MeSH-major] Hepatitis C, Chronic / epidemiology. Kidney Transplantation / adverse effects. Renal Dialysis / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064722.001).
  • [ISSN] 1052-9276
  • [Journal-full-title] Reviews in medical virology
  • [ISO-abbreviation] Rev. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin
  • [Number-of-references] 118
  •  go-up   go-down


99. Huang E, Samaniego-Picota M, McCune T, Melancon JK, Montgomery RA, Ugarte R, Kraus E, Womer K, Rabb H, Watnick T: DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease. Transplantation; 2009 Jan 15;87(1):133-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease.
  • Autosomal dominant polycystic kidney disease (ADPKD) is characterized by age-dependent growth of kidney cysts with end-stage renal disease developing in approximately 50% of affected individuals.
  • Living donors from ADPKD families are at risk for developing ADPKD and may be excluded from renal donation if the diagnosis cannot be conclusively ruled out.
  • Radiographic imaging may be adequate to screen for kidney cysts in most at-risk donors but may fail to identify affected individuals younger than 40 years or older individuals from families with mild disease.
  • In this article, we report a strategy that incorporates genetic testing in the evaluation of live kidney donors at risk for ADPKD whose disease status cannot be established with certainty on the basis of imaging studies alone.

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Polycystic Kidney Disease.
  • Genetic Alliance. consumer health - Polycystic kidney disease, adult type.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2001 May;12(5):955-63 [11316854.001]
  • [Cites] J Am Soc Nephrol. 2009 Jan;20(1):205-12 [18945943.001]
  • [Cites] Radiology. 2001 Dec;221(3):628-32 [11719656.001]
  • [Cites] Kidney Int. 2002 May;61(5):1588-99 [11967008.001]
  • [Cites] N Engl J Med. 2002 Dec 5;347(23):1867-75 [12466512.001]
  • [Cites] Clin Radiol. 2003 Aug;58(8):626-9 [12887956.001]
  • [Cites] Am J Transplant. 2004 Oct;4(10):1703-8 [15367228.001]
  • [Cites] Am J Kidney Dis. 1983 May;2(6):630-9 [6846334.001]
  • [Cites] Kidney Int. 1984 Aug;26(2):190-3 [6389956.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):332-42 [8321262.001]
  • [Cites] Lancet. 1994 Apr 2;343(8901):824-7 [7908078.001]
  • [Cites] Hum Mol Genet. 1997 Sep;6(9):1473-81 [9285784.001]
  • [Cites] Lancet. 1999 Jan 9;353(9147):103-7 [10023895.001]
  • [Cites] J Am Soc Nephrol. 2006 Nov;17(11):3013-9 [17035604.001]
  • [Cites] Lancet. 2007 Apr 14;369(9569):1287-301 [17434405.001]
  • [Cites] J Am Soc Nephrol. 2007 Jul;18(7):2143-60 [17582161.001]
  • [Cites] Mol Genet Metab. 2007 Sep-Oct;92(1-2):160-7 [17574468.001]
  • [CommentIn] Transplantation. 2009 Jan 15;87(1):6-7 [19136884.001]
  • (PMID = 19136903.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073704; United States / NIDDK NIH HHS / DK / R21DK071792; United States / NHLBI NIH HHS / HL / P0 HL073944; United States / NIDDK NIH HHS / DK / DK076017-03; United States / NHLBI NIH HHS / HL / R01 HL073944; United States / NIDDK NIH HHS / DK / R01DK70617; United States / NIDDK NIH HHS / DK / R01 DK54770; United States / NIDDK NIH HHS / DK / R01 DK054770; United States / NIDDK NIH HHS / DK / R01 DK076017-03; United States / NIDDK NIH HHS / DK / R21 DK071792; United States / NIGMS NIH HHS / GM / R01GM073704; United States / NIDDK NIH HHS / DK / R01 DK076017
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TRPP Cation Channels; 0 / polycystic kidney disease 1 protein; 9007-49-2 / DNA
  • [Other-IDs] NLM/ NIHMS107850; NLM/ PMC2841023
  •  go-up   go-down


100. Boobes Y, Bernieh B, Saadi H, Raafat Al Hakim M, Abouchacra S: Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol; 2010 Jun;42(2):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus.
  • We report our clinical experience with sirolimus-induced gonadal dysfunction and infertility in both male and female kidney transplant patients.
  • Of the 170 kidney transplant patients, nine (5.3%) patients (six males and three females) were receiving sirolimus.
  • [MeSH-major] Gonads / drug effects. Gonads / physiopathology. Immunosuppressive Agents / adverse effects. Infertility / chemically induced. Kidney Transplantation. Sirolimus / adverse effects






Advertisement